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This thesis describes novel synthetic methodologies for the synthesis of biologically 
relevant organofluorine compounds. Chapter 1 outlines the recent trends in this area and our 
synthetic procedures for the preparation of the gem-difluoromethylene analogues of the 
biologically active dipeptides, carnosine and carcinine. Synthesis of the latter compounds has 
been achieved using the fluorinated building block approach. Thus reaction of gem-difluoro-~­
alanine with histidine methyl ester dihydrochloride or histamine dihydrochloride using N-
benzyloxycarbonyl (N-Cbz) protecting strategy and EDCVHOBt peptide coupling protocol gave 
the gem-difluorinated version of the peptides carnosine and carcinine respectively. The gem-
Difluoro analogue of ~-alanine was prepared from a fluorine synthon, ethyl bromodifluoroacetate 
using Reforrnatsky reaction conditions. 
Chapter 2 is focused on development of novel synthetic method for the preparation of 
gem-difluorodiarylmethanes from the corresponding carbonyl compounds. Thus, 2,2-diaryl-1,3-
dithiolanes, readily obtainable from the corresponding diaryl ketones, were converted to the 
corresponding gem-difluorodiarylmethanes using a novel reagent combination SelectfluorR and 
Olah's reagent, pyridinium polyhydrogen fluoride (PPHF). This reaction is convenient, effective, 
and requires simple workup and mild reaction conditions. The reaction, although broadly 
applicable for diaryl ketones, is not useful for the preparation of their aliphatic versions. 
Chapter 3 delineates the preparation of trifluoromethylated arylsulfonamides by 
nucleophilic trifluoromethylation of aromatic N-tosylaldimines using trifluoromethyl 
trimethylsilane in the presence of N-heterocyclic carbene as a catalyst. N-heterocyclic carbene 
was produced in situ through the reaction from imidazolium chloride and potassium tert-
butoxide. Aromatic N-tosylaldimines with both electron-withdrawing and electron-donating 
groups underwent facile trifluoromethylation in the presence ofN-heterocyclic carbene to afford 
the corresponding trifluoromethylated sulfonamides in moderate to good yields. However, further 
optimizations are needed for the trifluoromethylation of aliphatic imines using this reagent. 
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1. SYNTHESIS OF gem-DIFLUOROMETHYLENE ANALOGUE OF 
CARNOSINE AND gem-DIFLUOROMETHYLENE CARCININE 
1.1 INTRODUCTION: 
1.1.1 Fluorinated versions of peptide analogues/mimetics: Peptide analogues are 
widely used to elucidate structure - activity relationships, and replacement of the peptide 
backbone with hydroxyrnethylene, ketomethylene, alkene, and other amino acid isosteres 
has led to significant increases in bioavailability and oral activity. 1-3 The introduction of 
fluorine into biologically active compounds can impart unique changes in physical, 
chemical, and biological properties in those compounds.4'5 Fluorinated peptide analogues 
are of particular interest in this regard.6-8 Various fluorine containing peptide analogues 
have been reported in the literature. Among them, peptide mimetics containing fluorine 
moieties such as fluorinated methyl ketones, difluorostatone, difluorostatine, difluoro 
ketomethylene, monofluoro ketomethylene, monofluoro hydroxyethylene, fluoroalkene, 
and (trifluoromethyl)alkene are well developed and used for biological activity studies.9 
1.1.2 Synthetic methods for selected fluorinated peptide analogues: Fluorinated 
peptide analogues have been of particular importance in the development of inhibitors of 
carboxylic ester and peptide hydrolases.8' 10-13 Brodbeck and co-workers first developed 
the fluorinated aldehydes and ketones and described their use as inhibitors of 
acetylcholinesterase. 14 Later, many different types of fluorinated peptide analogues were 
synthesized and studied for their structure-activity relationships and inhibitory activities 
towards aspartyl proteases, zinc metalloproteases, serine proteases, etc. General synthetic 
methods for selected fluorinated peptide analogues are discussed here. 
Native peptide substrate 
H 0 R2 H /yN0N~N'/ 
0 R1 H 0 
Fluorinated peptide mimetics/isosteres 
H 0 H 0 0 I N0 /yNYxJlN..-\ Y CFnH(3-n) 
0 R1 0 R1 F F H 
Fluorinated methyl ketones Difluorostatone 
H 0 R2 H H OH 0 
/yNY)clyNy /yNyl;(lN..-\ 
0 R1 F F 0 0 R1 F F H 
Difluoro ketomethylene Difluorostatine 
H 0 R2 H R1 OH R2 
/yN0ArN'f 1~H R1.N N'/ 
0 R1 F 0 F 0 
Monofluoro ketomethylene Monofluoro hydroxyethylene 
H R2 H H CF3 R2 H 
/yNyYyNy /yNyvyN'/ 
0 R1 F 0 0 R1 0 
Fluoroalkene (Trifluoromethyl)alkene 
Figure 1.1: Structural representations of selective fluorinated peptide 
analogues/mimetics/isosteres 
2 
1.1.2.1 Difluorostatone and difluorostatine peptide analogues: Peptides which contain 
difluorostatin and difluorostatone residues have been shown to be potent inhibitors of the 
renin. 15-18 Renin is an aspartyl protease, 19-22 which cleaves the circulating a-globulin 
angiotensinogen to form the decapeptide angiotensin I. Angiotensin I is further converted 
to octapeptide angiotensin II by the angiotensin converting enzyme. Interest in the 
3 
blockade of the rennin has led to development of the highly potent inhibitors, which 
contain difluorostatin and difluorostatone moieties. The introduction of electron-
withdrawing fluorine atoms adjacent to the carbonyl groups increases the electrophilicity 
of the carbonyl and thus facilitates the hydration of the ketone. The hydrated difluoro 
ketone was proposed to mimic the tetrahedral intermediate which forms during the 
enzyme-catalyzed hydrolysis of the peptide bond and thus acts as transition state 
analogue renin inhibitor. 16 The difluorostatone analogue has shown higher inhibitory 
activity than the corresponding nonfluorinated statone and difluorostatine analogues. 17 
H OH 0 yN~~ 
= F F y 
H 0 0 YN~I 
= F F y 
Difluorostatine analogue Difluorostatone analogue 
Figure 1.2: Structures of difluorostatine and difluorostatone analogues 
H 0 0 YN~I 
= F F y 
+ 
Difluorostatone analogue Trasition state analogue inhibitor 
Figure 1.3: Hydration of difluorostatone peptide analogue 
Thaisrivongs and co-workers have reported the synthesis of the potent renin 
inhibitors with difluorostatine and difluorostatone residues usmg ethyl 
bromodifluoroacetate as fluorine synthon. 16' 18 As shown in Figure 1.4, N-Boc-leucine 1.1 
4 
was reacted with ethyl bromodifluoroacetate usmg activated zmc dust to afford 
diastereomeric adducts 1.2a and 1.2b. The ester 1.2b was hydrolyzed using sodium 
hydroxide and the resulting salt 1.3 was coupled to L-isoleucyl-2-pyridylmethylamine 
(H-Ile-AMP) using N,N'-dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole 
(HOBt) to obtain the adduct 1.4. Two more a~ino acids were sequentially added to the 
compound 1.4 using diethylphosphoryl cyanide (DEPC) with triethylamine as coupling 
reagent to obtain the intermediate 1.5. The peptide analogue with difluorostatine residue 
1.6 was obtained by removal of tosyl group on histidine from the intermediate 1.5 using 
1-hydroxybenzotriazole. The peptide analogue with difluorostatone residue 1. 7 was 
prepared by oxidation of hydroxy group from compound 1.5 using Swem oxidation 
conditions followed by removal of tosyl group on histidine. 
0 
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Figure 1.4: Synthetic procedure for difluorostatine and difluorostatone analogues 
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1.1.2.2 Difluoroketomethylene peptide isostere: The hydrated form of 
difluoroketomethylene motif resembles the putative tetrahedral intermediate I, m 
proteolytic cleavage of the peptide bond and differs only in the substitution of 
difluoromethylene for tetrahedral nitrogen.23 
protease 
Protease Substrate I. Tetrahedral Intermediate 
R F F 0 "N~ H HO OH R 
II. Ketodifluoromethylene Dipeptide Isostere 
Figure 1.5: Hydration of peptide bond and difluoro ketone 
Hoover has reported the synthesis of ketodifluoromethylene dipeptide isostere 
usmg difluorodibromomethane (CF2Br2) as difluoromethylene source23 as shown in 
Figure 1.6. The aldehyde 1.8 was difluoromethylenated using difluorodibromomethane 
followed by successive desilyalation using sodium hydroxide to obtain the compound 
1.9. Compound 1.9 was esterified by sequential treatment with n-BuLi and 4-
methylvaleryl chloride to give the compound 1.10. Enolisation of 1.10 with LiN(TMS)2 
in THF, sequential addition of HMPA and tert-butyldimethylsilyl chloride in THF and 
hydrolysis gave the product 1.11. The imino ester 1.12 was prepared from the acid 1.11 
by reacting with ammonia in the presence of oxalyl chloride, and successive 0-alkylation 
7 
with Meerwin salt (Et30BF4). The iodocyclization of imino ester 1.12 was done to obtain 
cyclic imidate 1.13 by the reaction of 1.12 with the mixture of iodine, sodium bicarbonate 
and catalytic amount of 4,4'-thiobis(2-tert-butyl-6-methylphenol) (TBP) in 1:1 
dichloromethane-H20 in the dark at 25 °C for 24h. Hydrolysis of 1.13 with HCl in 2:1 
THF-H20 produced acyclic hydrochloride, which was further converted to the benzyl 
carbamate 1.14 using Cbz-Cl. Iodide 1.14 was converted to the protected amino alcohol 
1.15 by facile stereospecific hydrolysis under neutral conditions upon exposure to 
buffered peroxytrifluoroacetic acid in dichloromethane. The target difluoroketomethylene 
peptide mimic 1.16 was obtained by modified Pfitzner-Moffatt oxidation of amino 
alcohol 1.15 using 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride and 
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Figure 1.6: Synthetic procedure for difluoroketomethylene peptide isostere 
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1.1.2.3 Monofluoro ketomethylene peptide isostere: Monofluoroketomethylene peptide 
isosteres are very interesting peptide isosteres since the carbonyl group which is present 
adjacent to the monofluoromethylene group can be only partially hydrated in the presence 
of water so that interaction with several different types of protease is possible. There have 
been few reports on the synthesis of this type of peptide isosteres and peptide core 
units?4-26 In 1999, Hoffman has reported highly stereocontrolled synthesis of monofluoro 
ketomethylene dipeptide isosteres using Selectfluor as fluorinating reagent as shown in 
Figure 1.7.27 
According to Hoffinan's synthesis, tritylated amino acids 1.17 containing 
branched, unbranched, and heteroatom-containing side chains were converted to allyl ~­
ketoesters 1.18 in two steps using CDI, and LDA and allyl acetate. These ally keto esters 
1.18 were alkylated with scalemic triflates 1.19, and decorboxylated to provide tritylated 
ketomethylene isosteres 1.20. The diastereoselectivity in the reaction, alkylation-
decarboxylation of allyl ~-ketoesters was quite good, ranging from 85-95% de. In this 
reaction, Palladium(O) not only cleaved the allyl group selectively but also catalyzed the 
decarboxylation to give tritylated ketomethylene isosteres as a mixture of diastereomers 
1.20a and 1.20b. The syn isomer of 1.20a was converted to the corresponding (Z)-TMS 
enol ether 1.21 using NaHDMS-TMSCl. The bulky nitrogen substituent, trityl group on 
amino ketone caused the enolate formation to occur regiospecifically distal from the 
amino group by removal of a' -proton. And also the use of NaHDMS under kinetic 
conditions allowed the formation of only (Z) geometrical TMS enol ether 1.21. Later, the 
treatment of silyl enol ether 1.21 with Selectfluor in the presence of tetrabutylammonium 
10 
fluoride (TBAF) led to smooth a' -fluorination to produce monofluoro ketomethylene 
































TrHN F 0 NHTr 0 
1.22 1.21 
Figure 1.7: Synthetic procedure for monofluoro ketomethylene peptide isostere 
1.1.2.4 Monofluoro hydroxyethylene peptide isostere: HIV protease is one of the most 
significant protease targets in anti-infective therapy today. The inhibition of HIV protease 
has shown to extend the length and improve the quality of life of AIDS patients. The 
development and large-scale production of the stereochemically complex HIV protease 
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inhibitor indinavir by team of Merck scientists is one of the great recent achievements in 
the pharmaceutical industry.28'29 Later, Myers and co-workers have synthesized all the 
four diasteromers of stereospecific fluorine substituted hydroxyethylene dipeptide 
isosteres of indinavir in search for higher potencies and properties. 30 Synthesis of 
anti,anti isomer of fluorine substituted indinavir which was developed by Myers and co-
workers is presented here. 
Nitroalkene 1.23 was reacted with the cold solution ( -78 °C) of the lithium enolate 
derived from pseudoephedrine a-fluoroacetamide 1.24 to obtain the two distereomers 
(ratio anti:syn = 1.7:1) of the conjugate addition product 1.25 which differs in only the~­
center. Diastereomerically pure anti isomer of 1.25 was obtained by recrystallization and 
subjected to hydrolysis of the amide using 2N NaOH followed by diazomethylation using 
oxalyl chloride and trimethylsilyldiazomethane to obtain the diazomethyl ketone 1.26. 
Diazomethyl ketone was converted to tetrahydropyranyl ether 1.27 in three-step sequence 
involving bromination using hydrobromic acid, reduction of fluoro ketone to form anti 
configured fluorohydrin using sodium borohydride, and protection of alcohol using 3,4-
2H-dihydropyran (DHP). Nitroalkene 1.27 was converted to the corresponding 
carboxylic acid upon sequential treatment with potassium tert-butoxide and potassium 
permanganate in a buffered mixture of tert-butanol and water. The crude acid was 
coupled with (1S,2R)-l-aminoindan-2-ol to afford amide and tetrahydropyranyl ether was 
cleaved to obtain hydroxyamide 1.28. The hydroxy amide within the resultant diol was 
selectively protected using 2-methoxypropene and catalytic methanesulfonic acid. The 
resultant bromohydrin with protected hydroxy amide was reacted with potassium tert-
butoxide in THF at 0 °C to obtain the epoxide 1.29. Epoxide 1.29 was converted to 
12 
compound 1.31 by reacting with pyrazine 1.30 in 2-propanol followed by deprotection of 
benzyl carbamate by hydrogenolysis. Finally, alkylation of the secondary amine with 3-
picolyl chloride hydrochloride and acidic methanolysis of the acetonide protecting group 
afforded the anti,anti isomer of fluorine substituted hydroxyethylene dipeptide isostere 
of indinavir 1.31. 
CH3 0 
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Figure 1.8: Synthetic procedure for monofluoro hydroxyethylene peptide isostere 
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1.1.2.5 Fluoroalkene and (trifluoromethyl)alkene peptide isosteres: The fluoroalkene 
group has been regarded as an isosteric replacement for the peptide bond on the basis of 
"t 1 d d" . f 1 . . 8 31 32 s 1 1 s p anar geometry an trechon o po anzahon. ' ' evera groups have reported the 
synthetic methods for these fluoroalkene peptide isosteres in the literature. 33-40 In 1995, 
Bartlett has synthesized tripeptide analogues with trans-fluoroalkene moiety to study 
their structure-activity relationships and inhibitory properties towards zinc endopeptidase 
thermolysin.41 The synthetic procedure developed by Bartlett is discussed here. 
The mono protected diol 1.32 was oxidized to the aldehyde using Pyridinium 
chlorochromate (PCC) and condensed with diethyl fluorooxalate to obtain fluoroacrylate 
as a mixture of 1:2.3 mixture of E:Z isomers 1.33a and 1.33b. Diethyl fluorooxalate was 
prepared in situ in the reaction using diethyl oxalate and ethyl fluoroacetate. The Z-
isomer of 1.33b was separated by column chromatography and converted to allylic 
carbamate 1.34 by a three-step sequence involving amidation using ammonia in 
methanol, reduction to amine using lithium aluminium hydride (LiAlH4), and protection 
of amine with benzyl chloroformate (Cbz-Cl). The silyl ether was deprotected and the 
homoallylic alcohol was oxidized to acid to obtain the compound 1.35. Finally, the 
coupling of acid 1.35 with phenyl alanine methyl ester using dimethylaminopropyl-3-
ethyl carbodiimide (EDCI) and HOBt, and hydrolysis of the ester by lithium hydroxide 
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Figure 1.9: Synthetic procedure for fluoroalkene peptide isostere 
Electrostatically, the (trifluoromethyl)alkene represents a better match of the 
amide bond than any other common alkene isostere. In 1998, Wipf and co-workers have 
reported the synthesis of (trifluoromethyl)alkene dipeptide isostere usmg 
trifluorotrichloroethane as trifluoromethyl group source.42 The synthetic procedure 
developed by Wipf and co-workers is discussed here. 
Carboxylation of trifluorotrichloroethane 1.37, esterification with benzyl alcohol 
(BnOH), and Reformatsky addition-elimination with acetaldehyde yielded the 
trifluoroalkene as a 2:3 mixture of (E)- and (Z)-isomers 1.38a and 1.38b. The (Z)-isomer 
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1.38b was isolated by column chromatography and subjected to Sharpless asymmetric 
dihydroxylation. The resulting diol obtained from Sharpless asymmetric dihydroxylation 
was converted to epoxide using Mitsunobu reaction conditions. Later, the reduction of 
benzyl ester to aldehyde using diisobutylaluminium hydride (DIBAL-H) and Witig chain 
extension of the resulting aldehyde provided the alkenyl oxirane 1.39. Akenyl oxirane 
1.39 was converted to compound 1.40 by azide opening of epoxide, Straudinger 
reduction of azide to amine, conversion of amine to carbamate, and mesylation of 
alcohol. Finally, the allylic SN2' displacement of the mesylate and transamidation of the 
methyl ester provided the target (trifluoromethyl)alkene dipeptide isostere 1.41. 
1. Zn, CuCI, C02 (650 psi) 
2. BnOH, DCC, DMAP 
F3C - Cl3 -----------
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Figure 1.10: Synthetic procedure for (trifluoromethyl)alkene peptide isostere 
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1.1.2.6 Fluorinated amino acids and peptides: a-hydroxy-~-amino acids are well 
represented in a large number of biologically active compounds such as HN protease 
inhibitors, antitumor agents, and immunological response modifiers. Due to the 
enhancement of pharmacological properties by the incorporation of fluorine into the 
molecules, interest arose in the synthesis of fluorine containing a-hydroxy-~-amino acids 
which can serve as important bioactive compounds for medicinal chemistry and chemical 
biology. Kuznetsova and co-workers have reported a new synthetic approach to fluorine-
containing a-hydroxy-~-amino acids and their congeners from enantiopure 
trifluoromethyl containing ~-lactams using the ~-lactam synthon method.43 First, N-p-
methoxyphenyl trifluoroacetaldimine 1.42 was subjected to [2+2] ketene-imine cyclo 
addition using benzyloxyacetyl chloride as the ketene precursor to obtain racemic cis-3-
benzyloxy-4-trifluoro-methyl- ~-lactam (±)-1.43. The benzyl protecting group was 
changed to acetyl group by hydrogenolysis followed by acetylation to obtain the racemic 
cis-3-acetoxy-4-trifluoromethyl- ~-lactam (±)-1.45. Racemic 1.45 was subjected to 
enzymatic optical resolution using PS-Amano lipase to obtain optically pure (3R,4R)-3-
acetoxy-4-trifluoromethyl- ~-lactam (+)-1.45 and (3s, 4s)-3-hydroxy-4-trifluoromethyl-
~-lactam (-)-1.44. Hydroxy group was protected using triisopropylsilyl group in (-)-1.44 
and ( + )-1.44 followed by the removal of N-p-methoxyphenyl group using eerie 
ammonium nitrate to obtain the precursors (+)-1.46 and (-)-1.46 for N-acetylation as 
shown in Figure 1.11. An alternative method was also developed for the preparation of 
4-trifluoro-~-lactams involving the removal of N-protectingp-methoxyphenyl group from 
the racemic cis-3-acetoxy-4-trifluoromethyl- ~-lactam (±)-1.47 prior to enzymatic 
resolution as shown in Figure 1.12. 
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Figure 1.12: Alternative method for the preparation for 4-trifluoro-~-lactam 
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Later, the fluorinated P-lactam derivatives were transformed to fluorinated amino 
acids, dipeptide and taxoids. Fluorinated a-hydroxy-p-amino acids 1.50 were prepared by 
N-acylation of the resulting P-lactams 1.49 followed by hydrolysis. Trifluoromethyl 
containing a-hydroxy-P-amino acid methyl esters 1.51 were prepared by methanolysis of 
P-lactams. Trifluoromethyl containing dipeptides 1.52 and 1.53, and taxoids 1.54 were 
obtained by coupling P-lactams with amino acid esters and baccatins, respectively. 
/ 
_\ 0 Rr 0 0 ~O)lN¥N~OEt 








Figure 1.13: Transformation of fluorinated P-lactams to fluorinated amino acids, 
peptides and taxoids 
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The trifluoromethyl group is frequently used as a mimic for various functional 
groups such as methyl, isopropyl and phenyl, and is found in a number of biologically 
active and therapeutic agents.44A5 The trifluoromethyl group is hydrophobic, bulky and 
electron-rich. It enhances the in vivo stability of a compound as the removal or 
substitution of a fluorine in the trifluoromethyl group (as opposed to its methyl isosteres) 
cannot be easily done by metabolic enzymes.46 Jacobson and co-workers have described 
a new family of potent peptidomimetic hydroxamate inhibitors against matrix 
metalloproteases.47,48 Later, Zanda and co-workers incorporated fluoroalkyl substituents 
at the quartemay position and synthesized molecule such as 1.62.49 The synthesis of 
fluoroalkyl peptidomimetic hydroxamate 1.62 reported by Zanda and co-workers is 
presented here. 
The core malic unit with a-trifluoromethyl group was obtained by TiCl4 catalyzed 
Aldol reaction of N-acyl-oxazolidine-2-thione 1.55 with ethyl trifluoropyruvate 1.56. 
This gave 2.7:1 mixture of diastereomeric adducts 1.57a and 1.57b. The oxazolidin-2-
thione was cleaved from 1.57a using potassium carbonate to obtain the carboxylic acid 
derivative and the resulting carboxylic acid was coupled with 1.60 using HOAt/HATU. 
The coupling reaction generated the ~-lactam 1.59 in addition to the expected coupling 
product 1.61. The ~-lactam 1.59 was then separated and converted to coupling product 
1.62. Later, the coupled product 1.61 was converted to the final trifluoromethyl 
peptidomimetic hydroxamate 1.62 by saponification followed by coupling with benzyl 












YcH HO r:O,Et 
1.58 
Figure 1.14: Synthetic procedure for trifluoromethyl peptidomimetic hydroxamate 
21 
Rhodopeptins, a new family of antifungal cyclic lipopeptides, were isolated from 
Rhodococcus species Mer-N1033.50-52 They are composed of three a-amino acids and one 
~-amino acid with a lipophilic side chain. These Rhodopeptins have attractive fungicidal 
activities along with their unique structural characteristics. In 2000, Ohta and co-workers 
have reported their structure-activity relationship (SAR) studies on these molecules. 53 In 
their continuation work, they have reported the synthesis of difluoro54 analogues of 
Rhodopeptin in the pursuit of identifying new Rhodopeptin analogues with decreased 
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toxicity and improved physiochemical properties.55 The synthesis of gem-difluoro 
analogues of Rhodopeptin which was reported by Ohta and co-workers is discussed here. 
The aldehydes 1.63 was reacted with ethyl bromodifluoroacetate under 
Reformatsky conditions and followed by hydrolysis of ester using sodium hydroxide, 
formation of p-methoxy phenyl amide (PMP) using p-anisidine and Bis-(2-oxo-3-
oxazolidinyl)-phosphinyl chloride (Bop-Cl) to obtain a-gem-difluoro-~-hydroxy amide 
1.64. Intramolecular Mitsunobu reaction of 1.64 using diethyl azodicarboxylate (DEAD) 
and triphenylphosphine (PPh3) afforded the racemic ~-lactam 1.65. The ring opening of 
~-lactam 1.65 using sodium methoxide (MeONa) afforded the fully protected gem-
difluoro- ~-amino acid 1.66. The amino protecting conversion was accomplished by 
treatment with eerie (IV) ammonium nitrate (CAN) and di-tert-butyl carbonate ((Boc)20) 
which was necessary for the purification of the intermediate. After removal of the Boc 
group using trifluoro acetic acid (TFA) to obtain 1.67, conventional methods for peptide 
synthesis were used to obtain the gem-difluoro analogues of Rhodopeptin 1.68a and 
1.68b. These gem-difluoro analogues retained the antifungal activity of the non-
derivatized Rhodopeptins and displayed improved physical properties such as less 
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Figure 1.15: Synthetic procedure for gem-difluoro analogue ofRhodopeptin 
1.2 RESULTS AND DISCUSSIONS 
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Carnosine W-alanyl-L-histidine), a naturally occurring dipeptide, has unique role 
as antioxidant and antiglycating agent. 56-61 Based on these unique properties, it is able to 
attenuate cellular oxidative stress and can inhibit intracellular formation of ROS and 
RNS. The attenuation of oxidative stress by carnosine can involve sequestering of ROS 
or chelation of metal ions. Structurally related compounds such as carcinine, and anserine 
also show antioxidant and neuronal protecting activities. 62-64 
H 
N~N~NH2 tz.~ -A o 
N 0 OH 
H 
Carnosine Carcinine Anserine 
Figure 1.16: Structures of Carnosine, Carcinine, and Anserine 
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Although carnosine is abundantly present in excitable and nervous tissues (as high 
as 20 mM) in humans, its in vivo antioxidant properties are limited as it can be 
hydrolyzed to its constituent amino acids, histidine and P-alanine by serum carnosinase 
enzyme.65 -67 Dietary supplementation of carnosine is shown to prevent the development 
of ischemic/reperfusion induced acute renal failure.68 In light of its promising medicinal 
importance, there is lot of interest in developing analogues of carnosine with higher 
antioxidant, neuroprotective abilities and enzymatically stable analogues. Na-
acetylcarnosine 1.69, for example, is somewhat resistant to hydrolysis by carnosinase and 
is used as a prodrug for opthamic use.62 In 1999, Pinnen and co-workers reported the 
synthesis of sulfonamide peptide isosteres of carnosine, anserine, and isoanserine 1. 70-
1. 72 and studied their bioactivity. 69 These compounds have been reported to show higher 
stabilities towards carnosinase activity. In 2005, the same group have reported new 
synthetic carnosine analogues containing L(+)2,3-diaminopropanoic acid and studied the 
effect of N-acetylation on biochemical properties of carnosine.70 Mono- and bis-
acetylated compounds 1.73 and 1.74 are resistant to enzymatic hydrolysis by carnosinase 
and also act as competitive inhibitors of this enzyme. These compounds have shown 
identical hydroxy radical scavenging abilities to that of carnosine and also act as 
protective agents against peroxynitrite-dependent damage as determined by their ability 
25 
to prevent nitration of free tyrosine induced by this peroxynitrite radical. In 2005, Guiotto 
and coworkers have reported the synthesis and neuroprotective abilities of histidyl 
containing carnosine analogues 1.75-1.77 bearing hydrazide or 1,2-diol moieties.71 These 
carnosine analogues 1.75-1.77 have been demonstrated to show higher a,~-unsaturated 











Figure 1.17: Examples of reported carnosine analogues 
Introduction of gem-difluoromethylene group into orgamc compounds 
dramatically alters biological activities and imparts increased lipophilicity to the 
molecules.72•73 The gem-Difluoromethylene group adjacent to the amide carbonyl group 
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can significantly increase the electophilicty of the carbonyl group, which would result in 
more potent hydroxyl scavengers. In addition, these gem-difluoromethylene containing 
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Figure 1.18: Structures of synthesized gem-difluoromethylene analogues of carnosine 
and carcinine 
We envisioned that the preparation of gem-difluoro derivative of one of the 
amino acids present in the dipeptide and coupling with another amino acid of the 
dipeptide would accomplish the synthesis of gem-difluoro analogue of dipeptide. Both 
carnosine and carcinine have P-alanine as one of the amino acids, and for this reason, the 
preparation of gem-difluoro- P-alanine has attracted our attention. Later, gem-difluoro- P-
alanine was coupled with the respective amino acids to achieve the synthesis of gem-
difluoro analogues of carnosine and carcinine. 
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Figure 1.19: Retrosynthetic analysis ofthegem-difluoromethylene analogue ofL-
camosine 
H,FX ~ N~Nlf ...._,NH2 












Figure 1.20: Retrosynthetic analysis of the gem-difluoromethylene carcinine 
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1.2.1 Synthesis of gem-difluoromethylene analogue of L-carnosine: There have been 
several methods reported in the literature to prepare the fluoro-~-aminoacids.74 Among 
them, Reformatsky-type of reactions using halodifluoroacetate as fluorine building block 
28 
are widely used to prepare ~-substituted a, a-difluoro-~-aminoacid derivatives.75-80 
Protected verst on of gem-difluoro- ~-alanine, ethyl 3-( dibenylamino )-2,2-
difluoropropanoate 1.80 was prepared from N,N-(Bis-phenylmethyl)-benzotriazolyl-1-
methylamine81 '82 1.78 and ethyl bromodifluoroacetate 1.79 according literature 
procedure80 using Reformtsky reaction conditions. Compound 1.78 was reacted with 1.79 
in the presence of zinc dust activated with chlorotrimethylsilane at room temperature. 
The reaction was completed in 3h and gave ethyl 3-(dibenylamino)-2,2-
difluoropropanoate 1.80 in 88% yield after column chromatography purification. Next, 
the hydrolysis of ester group of 1.80 using IN LiOH afforded 3-(dibenzylamino)-2,2-
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Figure 1.21: Preparation ofN-benzyl protected gem-difluoro ~-alanine 
After the preparation of free acid, 3-(dibenzylamino)-2,2-difluoropropanoic acid 
1.81, different coupling methods were tested for the coupling with histidine methyl ester 
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hydrochloride to obtain the protected dipeptide in higher yields. First conventional 
coupling method, DCC/H0Bt83 was perfonned and obtained the product methyl 2-(3-
( dibenzylamino )-2,2-difluoropropanamido )-3-(lH-imidazol-4-yl)propanoate 1.83 in very 
less yield (31 %) even after 36 h of reaction time. Later, peptide bond formation was 
performed using more advanced methods using EDCI!H0Bt84 and BOP reagent85 
reagents. In both the cases, the product 1.83 was isolated in disappointing yields 42% and 
36% respectively. 
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Figure 1.22: Different methods forth~ peptide ~ond form~tion between ~istid.ine methyl 
ester hydrochloride and 3-(Dtbenzylarnmo )-2,2-dtfluoropropanmc acid 
Even the coupling reaction between 3-(dibenzylamino)-2,2-difluoropropanoic 
acid 1.81 and histamine dihYdrochloride using EDCIIHOBt in the presence of N-methyl 
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morpholine in DMF was not efficient and gave the product N-(2-(lH-imidazol-4-
yl)ethyl)-3-(dibenzylamino)-2,2-difluoropropanamide 1.85 in very low yield (26%). 
N~NH2 
( )\ + 




-20°C - RT, 24h 
Yield= 26% 
Figure1.23: Coupling reaction between histamine hydrochloride and 3-(dibenzylamino)-
2,2-difluoropropanoic acid 
The lower yield in the case of coupling between the above compounds may be 
explained in terms of high steric hindrance caused by the amine protecting, dibenzyl 
group. Later we have turned our attention towards the preparation gem-difluoro-~-
alanine derivative with less sterically demanding protecting group on amine. 
According to that, ethyl 2,2-difluoro-3-( 4-methoxyphenylamino )propanoate 1.88, 
which has p-methoxy phenyl group (PMP)86 as protecting group on amine was prepared 
according to literature procedure. 87 Ethyl 2,2-difluoro-3-( 4-
methoxyphenylamino )propanoate 1.87 was prepared by reacting ethyl 
bromodifluoroacetate with N-( 4-methoxy phenyl)-benzotriazolyl-1-methylamine 1.86 in 
the presence of zinc dust/chlorotrimethyl silane at 50 °C for 3h. Later, hydrolysis of ester 
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Figure 1.24: Preparation ofN-PMP protected gem-difluoro ~-alanine 
PMP-protected gem-difluoro- ~-alanine 1.88 was coupled with histidine 
methylester using EDCI/HOBt to prepare PMP-protected gem-difluoromethylene 
analogue of carnosine 1.89. In case of carnosine, the presence of free primary amine was 
responsible for its therapeutic activity. 71 Hence, we were interested in the deprotection of 
p-methoxy phenyl group from compound 1.89 to get the final compound gem-
difluoromethylene analogue of carnosine 1.90 with free primary amine group. 
Deprotection of p-methoxy phenyl group from 1.89 was attempted using eerie 
ammonium nitrate (CAN) mediated oxidative deprotection88 to get the final compound 
gem-difluoro analogue of carnosine 1.90. The reaction was not efficient and produced so 
many products corresponding to PMP deprotected and hydrolysis products of 1.89, and 
other uncharacterized products. Even after tedious work up and column chromatography 
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purification, the final compound gem-difluoro analogue of carnosine 1.90 was obtained in 
impure form and in very low yield (14%). 
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Figure 1.25: Synthesis of gem-difluoromethylene analogue of carnosine using PMP 
protecting method 
Because of the involvement of difficulties in the final deprotection step, the PMP 
protecting approach for the preparation of gem-difluoromethylene analogue of carnosine 
was not effective. Later, other protecting groups for amine such as carbonyl benzyloxy 
(Cbz) and tert-butoxy carbonyl (Boc) were opted to get the higher overall yields. 
According to that, N-( 4-benzyloxy carbonyl)-benzotriazolyl-1-methylamine 1.91 89 was 
prepared and reacted with ethyl bromodifluoroacetate in the presence of zinc dust and 
chlorotrimethylsilane to obtain gem-difluoro- ~-alanine ester with Cbz protecting group 
on amine 1.92. The reaction was not successful even at higher temperatures and longer 
reaction times, and all the starting material1.91 was recovered after the work up. 
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Figure 1.26: The preparation and reaction ofN-Cbz benzotriazolyl methylamine with 
ethyl bromodifluoroacetate 
After the unsuccessful attempt of Reformatsky reaction with 1.91, an indirect 
method was followed to prepare Cbz protected gem-difluoro-~-alanine. Ethyl 3-
( dibenzylamino )-2,2-difluoropropanoate 1.80 from first step was taken and the dibenzyl 
group was deprotected by hydrogenolysis in the presence of Pearlman's catalyst in dry 
ethanol containing trifluoroacetic acid to obtain trifluoroacetate salt of free ~-amino ester 
1.93. 8° Compound 1.93 was reacted with benzyl chloroformate in the presence of triethyl 
amine to obtain the Cbz protected gem-difluoro-~-alanine 1.92 in 78% yield. t-Boc 
protected gem-difluoro-~-alanine 1.9490 was also prepared from 1.93 using di-tert-butyl-
dicarbonate and pyridine . 
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Figure 1.27: Preparation ofN-Cbz and N-Boc protected gem-difluoro ~-alanine esters 
N-Cbz protected ~-amino ester 1.92 was hydrolyzed to free acid 1.95 using 1 N 
LiOH and coupled with histidine methylester hydrochloride using EDCIIHOBt in the 
presence of N-methyl morpholine in DMF to obtain protected version of gem-difluoro 
analogue of carnosine 1.96 in 78% yield. 
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Figure 1.28: Preparation ofN-Cbz protected gem-difluoromethyelene analogue of 
carnosme 
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Simultaneously, Boc protected gem-difluoro analogue of carnosine 1.98 was 
prepared from N-Boc protected gem-difluoro ~-amino ester 1.94 by hydrolysis of ester 
group using LiOH91 in 2:2:1 ratio of THF/MeOH/H20 followed by coupling with 
histidine methylester hydrochloride using EDCIIHOBt in DMF. 





RT, 12 h 
F F HO~NHBoc + N~NH2 {(_) -~ 
N oAoMe H 0 
1.97 .2 HCI 1.82 
EDCI, HOBT 
NMM, DMF 
-20 tO RT, 24h 
H F F N~N~NHBoc 
{(_)-A o 
N 0 OMe H 
1.98 
Figure 1.29: Preparation ofN-Boc-gem-difluoromethylene analogue of carnosine 
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With the both Cbz and Boc protected gem-difluoro analogues of carnosine in 
hand, the first deprotection of Cbz group from 1. 75 was attempted in order to prepare 
final compound gem-difluoro analogue of carnosine. Compound 1.75 was subjected to 
hydrogenolysis in the presence catalytic amount of Pd in MeOH. The reaction mixture 
was stirred for 36h, Pd was removed by filtration, and the solvent was evaporated to get 
the final compound (S)-methyl 2-(3-amino-2,2-difluoropropanamido )-3-(1 H -imidazol-4-
yl)propanoate 1.69 in very good yield (84%). The final Cbz deprotection reaction was 
simple, efficient and gave essentially pure final product the gem-difluoromethylene 
analogue of carnosine 1.69 in very good yield. 
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Figure 1.30: Synthesis of gem-difluoromethylene analogue of carnosine from Cbz 
protecting method 
Synthesis of gem-difluoromethylene analogue of carnosine 1.90 was achieved in 
seven steps starting from N,N-(bis-phenylmethyl)-benzotriazolyl-1-methylamine 1. 78 
with an overall yield of23.2%. 
1.2.2 Synthesis of gem-difluoromethylene carcinine: PMP protected gem-difluoro-P-
alanine 1.88 was coupled with histamine hydrochloride using EDCVHOBt in DMF to 
prepare the protected version of gem-difluoromethylene-carcinine, N-(2-(lH-imidazol-4-
yl)ethyl)-2,2-difluoro-3-( 4-methoxyphenylamino )propanamide 1.99. Later, deprotection 
of p-methoxy phenyl group from 1.99 was attempted using CAN mediated oxidative 
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deprotection method. Compound 1.99 was dissolved in acetonitrile, treated with aqueous 
solution of CAN, and the solution was stirred for 3h. After work up and purification of 
the residue, the final compound gem-difluoromethylene carcinine, N-(2-(lH-imidazol-4-
yl)cthyl)-3-amino-2,2-difluoropropanamide 1.100 was obtained in very low yield (22%) 
accompanied by some other uncharacterized products. 
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Figure 1.31: Synthesis of gem-difluoromethylene carcinine using PMP-protecting 
method 
Because of lower yields associated with PMP protecting grouping strategy, we 
have turned our attention to Cbz protecting grqup strategy which was proved to be 
effective in case of preparation of gem-difluoro analogue of carnosine. According to that, 
Cbz protected difluoro P-alanine 1.95 coupled with histamine methylester hydrochloride 
using EDCVHOBt in the presence of N-methyl morpholine in DMF to obtain the 
protected version of gem-difluoro analogue of carcinine 1.101 in 72% yield. Later, 
deprotection of the Cbz group from 1.101 was attempted to prepare the final compound, 
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gem-difluoromethylene carcinine 1.100. Compound 1.101 was subjected to 
hydrogenolysis in the presence of a catalytic amount of Pd in MeOH. The reaction 
mixture was stirred for 36h, Pd was removed by filtration, and the solvent was evaporated 
to get the final compound N-(2-(lH-imidazol-4-yl)ethyl)-3-amino-2,2-
difluoropropanamide 1.100 in very good yield (86%). The final Cbz deprotection reaction 
was simple, efficient and gave final product gem-difluoromethylene carcinine 1.100 in 
very good yield. 
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Figure 1.32: Synthesis of gem-difluoromethylene carcinine using Cbz-protecting method 
Synthesis of gem-difluoromethylene carcinine 1.100 was achieved in six steps 
starting from N,N-(bis-phenylmethyl)-benzotriazolyl-1-methylamine 1. 78 with an overall 
yield of 22%. 
1.3 CONCLUSIONS 
gem-Difluoromethylene analogues of carnosine and carcinine were synthesized in 
six steps starting from benzotriazolyl methylamines with an over all yields of23.2% and 
22% respectively. The synthetic method for these compounds mainly consists of the 
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preparation of N-Cbz protected a,a-dif1uoro-~-alanine and its coupling with histidine 
methylester dihydrochloride or histamine dihydrochloride followed by deprotection of 
Cbz group by hydrogenolysis. N-Cbz protected a,a-difluoro-P-alanine was prepared by 
deprotecting the dibenzyl group form N-dibenzyl protected a,a-difluoro-P-alanine ethyl 
ester and reprotecting the resulting free amine with benzyl chloroformate foiiowed by 
hydrolysis of ester. The reagent combination EDCUHOBT was found to be high yielding 
for the coupling of N-dibenzyl-protected a,a-difluoro-P-alanine and histidine methyl ester 
dihydrochloride and has been used for all the other coupling reactions. The final 
deprotection of Cbz group by hydrogenolysis using Pd/C was simple and gave high 
yields for the products. The developed synthetic procedure is simple, effective and can be 
used to incorporate the gem-difluoromethylene group in other biologically interesting 
peptides. 
1.4 EXPERIMENTAL RESULTS 
1.4.1 General: All reagents were purchased from commercial sources and used as 
received. Column chromatography was carried out using Merck 60, 230-400 mesh. Thin 
layer chromatography was carried out using silica gel coated polyester backed sheets. 
GC/MS spectra were recorded on Hewlett-Packard 5989A spectrometer, equipped with a 
Hewlett-Packard 5890 gas chromatograph. The 1H, 13C and 19F NMR spectra for CDCl3, 
CD30CD3 and CD30D solutions were obtained on a INOV A-Varian 400 MHz 
spectrometer at 400, 100, and 386 MHz, respectively. The 1H NMR, 13C NMR chemical 
shifts are referred to the residual solvents signals or the internal TMS (8 = 0.0). The 19F 
chemical shifts are referred to the internal CFCh (8 19F = 0.0). 
1.4.2 Synthesis and properties of products 








Benzotriazole (5.97 g, 50 mmol) and dibenzyl amine (10.85 g, 55 mmol) were dissolved 
in methanol (30 mL). To the resulting solution, 37% formaldehyde (4.5 mL, 60 mmol) 
was added. Solid was formed instantaneously. The formed solid was filtered and 
recrystallized from methanol to obtain the product N,N-(Bis-phenylmethyl)-
benzotriazolyl-1-methylamine 1. 78: yield 14.0 g (85%) 




Benzotriazole (5.97 g, 50 mmol) and p-anisidine (10.85 g, 55 mmol) were dissolved in 
methanol (30 mL). To the resulting solution, 37% formaldehyde (4.5 mL, 60 mmol) was 
added. Solid was formed instantaneously. The formed solid was filtered and 
recrystallized from methanol to obtain the product N-(4-methoxy phenyl)-benzotriazolyl-
!-methylamine 1.86: yield 7.7 g (85%) 
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N-( 4-benzyloxy carbonyl)-benzotriazolyl-1-methylamine (1.91) 
1-(Hydroxylmethyl)-benzotriazole (2g, 13.41 mmol), benzyl carbamate (2.03 g, 13.41 
mmol) and catalytic amount of toluene p-sulfinic acid monohydrate in 30 mL of toluene 
were refluxed for 15 h in an apparatus fitted with a Dean-Stark water separator. The 
mixture was cooled and the crystals formed were separated. Recrystallization from 
toluene gave the product 1.91: yield 2.6 g (70%) 
Ethyl3-(dibenylamino)-2,2-difluoropropanoate (1.80) 
~ FXF ~ r-Ph 
EtO If "'""N'-Ph 
0 
1.80 
To the suspensiOn of zinc dust (0.927 g, 14.1 mmol) in dry THF (15 m L ), 
chlorotrimethylsilane (1 mL, 7.9 mmol) was added under nitrogen atmosphere and stirred 
the mixture for 10 min. Ethyl bromodifluoroacetate (0.94 mL, 7.9 mmol) was added to 
the reaction mixture and stirred for 20 min, followed by the addition of N-(Bis-
phenylmethyl)-benzotriazolyl-1-methylamine 1. 78 (2. 7 g, 8.13 mmol) in THF (20 mL) 
dropwise and allowed the reaction mixture to stir for 3h at room temperature. Reaction 
was quenched with saturated NaHC03 and solids were filtered on celite 545. The filtrate 
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was extracted with ethyl acetate (3 x 30 mL), washed with brine and dried over MgS04. 
The solvent was evaporated and the residue was diluted with ether. The formed solid was 
filtered and the ether was evaporated, and purified the residue by column 
chromatography to give the product Ethyl 3-(dibenylamino)-2,2-difluoropropanoate 1.80 
as a colorless oil: yield 2.26 g (88%) 
1H NMR (400 MHz; CDCh) o 1.2 (t, J = 7.2 Hz, 3 H), 3.I4 (t, hH = I2.8 Hz, 2 H), 3.67 
(s, 4 H), 4.I6 (q, J = 7. 2Hz, 2 H), 7.26-7.36 (m, IO H) ppm. 
13C NMR (IOO MHz; CDCh) o I4.0I, 55.49 (t, 2Jc-F = 26.6 Hz), 58.75, 62.96, I16.53 (t, 
1Jc-F = 251.2 Hz), I27.57, I28.57, I29.42, I38.44, I64.09 (t, 2Jc-F = 31.9 Hz) ppm. 
19F NMR (376 MHz; CDCh/CFCh) o -I06.83 (t, J = 13.9 Hz) ppm. 
3-(Dibenzylamino )-2,2-difluoropropanoic acid (1.81) 
To the solution of Ethyl 3-( dibenylamino )-2,2-difluoropropanoate 1.80 (760 mg, 2.28 
mmol) in acetonitrile (10 mL), IN LiOH aqueous solution (10 mL) was added and the 
reaction mixture was stirred for 3h. The solvent was evaporated and diluted with water (5 
mL) and washed with ether (10 mL). The aqueous phase was acidified with IN HCl (until 
pH I) and extracted with ethyl acetate (3 x 20 mL). The solvent was evaporated, and the 
residue was purified by column chromatography to give the product 3-( dibenzylamino )-
2,2-difluoropropanoic acid 1.81: yield 0.52 g (74%) 
43 
I 
H NMR (400 MHz; CDCh) o 3.46 {t, J = 12.8 Hz, 2 H), 4.18 (s, 4 H), 7.29-7.38 (m, 10 
H), 10.98 (b, 1H)ppm. 
13C NMR (100 MHz; CD30CD3) o 55.74 (t, 2Jc-F = 26.6 Hz), 58.73 (t, 4Jc_F = 12.2 Hz), 
116.88 (t, 1Jc-F = 249.7 Hz), 128.13, 129.07, 130.02, 138.53, 165.11 (t, 2Jc_F = 31.2 Hz) 
ppm. 
19 F NMR (376 MHz; CD30CD3/CFCh) o -105.89 (t, J = 13.7 Hz) ppm. 
Methyl 2-(3-( dibenzylamino )-2,2-difluoropropanamido )-3-(lH-imidazol-4-
yl)propanoate (1.83) 
Procedure 1: 3-(Dibenzylamino )-2,2-difluoropropanoic acid 1.81 (1 06 mg, 0.34 7 
mmol), Histidine methylester hydrochloride (84 mg, 0.347 mmol) and 1-hydroxy 
benzotriazole (51.6 mg, 0.382 mmol) were taken in THF (10 mL), stirred under nitrogen 
atmosphere, and treated with 4-methylmorpholine (0.1 mL, 0. 7 mmol). The solution was 
cooled to 0 °C and added dicyclohexyl carbodiimide (71.5mg, 0.347 mmol) in 
dichloromethane (2.5 mL). The resulting solution was allowed to come slowly to room 
temperature and stirred for 24 h. The solvent was evaporated; saturated NaHC03 was 
added, and extracted with hot ethyl acetate (5 x 20 mL). The solvent was dried over 
MgS04 and concentrated. The residue was purified by column chromatography to give 
the product methyl 2-(3-( dibenzylamino )-2,2-difluoropropanamido )-3-( I H-imidazol-4-
yl)propanoate 1.83: yield 49 mg (31 %) 
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Procedure 2: 3-(Dibenzylamino )-2,2-difluoropropanoic acid 1.81 ( 106 mg, 0.34 7 
mmol), histidine methylester hydrochloride 7 (84 mg, 0.347 mmol) and !-hydroxy 
benzotriazole (51.6 mg, 0.382 mmol) were taken in dimethyl formamide (5 mL), stirred 
under nitrogen atmosphere, and treated with 4-methylmorpholine (0.1 mL, 0. 7 mmol). 
The solution was cooled to -20 °C and added dimethylaminopropyl-3-ethyl carbodiimide 
(73.3 mg, 0.382 mmol). The resulting solution was allowed to come slowly to room 
temperature and stirred for 24 h. The solvent was evaporated, saturated NaHC03 was 
added, and extracted with hot ethyl acetate (5 x 20 mL). The solvent was dried over 
MgS04 and concentrated. The residue was purified by column chromatography to give 
the product methyl 2-(3-( dibenzylamino )-2,2-difluoropropanamido )-3-( 1H-imidazol-4-
yl)propanoate 1.83: yield 66 mg (42%) 
Procedure 3: 3-(Dibenzylamino)-2,2-difluoropropanoic acid 1.81 (106 mg, 0.347 
mmol), histidine methylester hydrochloride 7 (84 mg, 0.347 mmol) and BOP reagent 
(154 mg, 0.347 mmol) were taken up in acetonitrile, stirred under nitrogen atmosphere, 
and treated with triethylamine (0.15 mL, 1.04 mmol). The mixture is stirred at room 
temperature for overnight. The precipitate was filtered off and washed with acetonitrile. 
Acetonitrile was evaporated, the residue was dissolved in ethyl acetate, washed with 2N 
HCl and saturated aqueous NaHC03. The organic layer was dried over MgS04, 
concentrated and purified by column chromatography to get the product methyl 2-(3-
( dibenzylamino )-2,2-difluoropropanamido )-3-( 1H-imidazol-4-yl)propanoate 1.83: yield 
57 mg (36%) 
1H NMR (400 MHz; CD30D) 8 3.12 (m, 2 H), 3.11 (m, 2 H), 3.63 (s, 3 H), 3.65 (s, 4 H), 
4.74 (m, 1 H), 6.85 (s, 1 H), 7.26 (m, 10 H), 7.54 (s, 1 H) ppm. 
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13c NM ( R 100 MHz; CD30D) 8 29.79, 52.90, 54.04, 55.88 (t, 2Jc_F = 25.8 Hz), 59.14, 
117.69, 118.41 (t, 1Jc-F = 252 Hz), 134.72, 136.48, 139.55, 166.05 (t, 2Jc-F = 28.9 Hz), 
172.41 ppm. 
19 F NMR (376 MHz; CD30D/CFCb) 8-108.31 (m) ppm. 
N-(2-(1H-imidazol-4-yl)ethyl)-3-( dibenzylamino )-2,2-diflu orop ropanamide (1.85) 
3-(Dibenzylamino )-2,2-difluoropropanoic acid 1.81 ( 200 mg, 0.656 mmol), histamine 
hydrochloride (121 mg, 0.656 mmol) and 1-hydroxy benzotriazole (97 .4 mg, 0. 721 
mmol) were taken up in dimethyl formamide (5 mL), stirred under nitrogen atmosphere, 
and treated with 4-methylmorpholine (0.15 mL, 1.31 mmol). The solution was cooled to 
-20 °C and added dimethylaminopropyl-3-ethyl carbodiimide (138 mg, 0. 721 mmol). The 
resulting solution was allowed to come slowly to room temperature and stirred for 24 h. 
The solvent was evaporated, saturated NaHC03 was added, and extracted with hot ethyl 
acetate (5 x 20 mL). The solvent was dried over MgS04 and concentrated. The residue 
was purified by column chromatography to give the product N-(2-(1H-imidazol-4-
yl)ethyl)-3-(dibenzylmino)-2,2-difluoropropanamide 1.85: yield 68 mg (26%) 
1 . H NMR (400 MHz; CD30D) 8 2.81 (t, J = 7.2 Hz, 2 H), 3.11 (t, J = 13.6 Hz, 2 H), 3.47 
(t, J = 7.2 Hz, 2 H), 3.63 (s, 4 H), 6.84 (s, 1 H), 7.27 (m, 10 H), 7.62 (s, 1 H) ppm. 
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13 C NMR (100 MHz; CD30D) 8 27.41, 40.39, 56.07 (t, 2Jc-r = 26.6 Hz), 59.30, 117.53, 
118.60 (t, 1Jc-F = 251.2 Hz), 128.20, 129.25, 130.07, 136.07, 139.59, 166.18 (t, 2Jc-F = 
28.8 Hz) ppm. 
19 F NMR (376 MHz; CD30D/CFCh) 8-107.93 (m) ppm. 
Ethyl 2,2-difluoro-3-( 4-methoxyphenylamino )propanoate (1.87) 
F F Ho-EtO~N ~ !J OMe 
0 
1.87 
To the suspensiOn of zmc dust (647 mg, 9.9 mmol), in dry THF (1 0 mL), 
chlorotrimethylsilane (0.63 mL, 4.95 mmol) was added under nitrogen atmosphere and 
stirred the mixture for 10 min. Ethyl bromodifluoroacetate was added to the reaction 
mixture and stirred for 20 min, followed by the addition of N-( 4-methoxy phenyl)-
benzotriazolyl-1-methylamine 1.86 (1.269 g, 4.95 mmol) in THF (15 mL) dropwise and 
the reaction mixture was stirred for 3h at 50 °C. Reaction was quenched with saturated 
NaHC03 and solids were filtered on celite 545. The filtrate was extracted with ethyl 
acetate, washed with IN HCl and dried over MgS04. The solvent was evaporated and the 
residue was diluted with ether. The formed solid was filtered and the ether was 
evaporated of, and purified the residue by column chromatography to give the product 




H NMR (400 MHz; CDCh) 8 1.25 (t, J = 7.2 Hz, 3 H), 3.70 (s, 3 H), 3.71 (t, J11 _F = 12.8 
Hz, 2 H), 4.22 (q, J = 7.2 Hz, 2 H), 6.62 (d, J = 8.8 Hz, 2 H), 6.75 (d, J = 9.2 Hz, 2 H) 
ppm. 
13C NMR (100 MHz; CDCh) 8 13.6, 48.15 (t, 2Jc-F = 27.3 Hz), 55.41, 62.90, 114.51 (t, 
1Jc-F = 251.3 Hz), 114.61, 114.77, 140.77, 152.85, 163.46 (t, 2Jc-F = 31.8 Hz) ppm. 
19 F NMR (376 MHz; CDCh/CFCh) 8-111.27 (t, J = 13.7 Hz) ppm. 
2,2-Difluoro-3-( 4-methoxyphenylamino )propanoic acid (1.88) 
F. F Ho-HO~N ~ /; OMe 
0 
1.88 
To the solution of Ethyl 2,2-difluoro-3-(4-methoxyphenylamino)propanoate 1.87 (1.2g, 
4.63 mmol) in acetonitrile (15 mL), IN LiOH aqueous solution (15 mL) was added and 
the reaction mixture was stirred for 3h. The solvent was evaporated, diluted with water (5 
mL) and washed with ether (10 mL). The aqueous phase was acidified with IN HCl (until 
pH l) and extracted with ethyl acetate (3 x 30 mL). The solvent was evaporated, and the 
residue was purified by column chromatography to give the product 2,2-difluoro-3-( 4-
methoxyphenylamino)propanoic acid 1.88: yield 0.79 g (74%) 
1H NMR (400 MHz; CD30CD3) 8 3.67 (s, 3 H), 3.77 (t, J = 14.4 Hz, 2 H), 6.73 (s, 4 H). 
13C NMR (100 MHz; CD30CD3) 8 48.51 (t, 2Jc-F = 27.6 Hz), 55.68, II5.27, 116.18 (m), 
142.68, 153.40, I65.I2 (m) ppm. 
19F NMR (376 MHz; CD30CD3/CFCh) 8 -II0.67 (t, J = 13.7 Hz) ppm. 
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Methyl 2-(2,2-difluoro-3-( 4-methoxyphenylamino )propanamido )-3-(1 H -imidazol-4-
yl)propanoate (1.89) 
2,2-Difluoro-3-(4-methoxyphenylamino)propanoic acid 1.88 (200 mg, 0.86 mmol), 
histidine methylester hydrochloride (210 mg, 0.86 mmol) and 1-hydroxy benzotriazole 
(129 mg, 0.95 mmol) were taken in dimethyl formamide (5 mL), stirred under nitrogen 
atmosphere, and treated with 4-methylmorpholine (0.2 mL, 1.8 mmol). The solution was 
cooled to -20 °C and added dimethylaminopropyl-3-ethyl carbodiimide (183 mg, 0.95 
mmol). The resulting solution was allowed to come slowly to room temperature and 
stirred for 24 h. The solvent was evaporated, saturated NaHC03 was added, and extracted 
with hot ethyl acetate (5 x 20 mL). The solvent was dried over MgS04 and concentrated. 
The residue was purified by column chromatography to give the product Methyl 2-(2,2-
difluoro-3-(4-methoxyphenylamino)propanamido)-3-(1H-imidazol-4-yl)propanoate 1.89: 
yield 235 mg (71 %) 
1H NMR (400 MHz; CD30D) o 3.01 (dd, J = 8.8 Hz, 14.8 Hz, 1 H), 3.12 (dd, J = 5.2 Hz, 
14.8 Hz, 1 H), 3.64 (m, 2 H), 3.66 (s, 3 H), 3.68 (s, 3 H), 4.68 (m,1 H), 6.63 (d, J = 8.8 
Hz, 2 H), 6.72 (d, J = 9.2 Hz, 2 H), 6.79 (s, 1 H), 7.53 (s, 1 H) ppm. 
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13C NMR (100 MHz; CD30D) 8 29.54, 48.78 (t, 2Jc-F = 28.1 Hz), 52.95, 54.07, 56.11, 
115.591, 115.67, 117.61 (t, 1Jc-F =252Hz), 117.78, 134.58, 136.43, 143.18, 153.88, 
165.99 (t, 2Jc-F = 28.9 Hz), 172.41 ppm. 
19 F NMR (376 MHz; CD30D/CFCb) 8-111.85 (m) ppm. 
3-Ethoxy-2,2-difluoro-3-oxopropan-1-aminium 2,2,2-trifluoroacetate (1.93) 
To a solution of Ethyl 3-(dibenylamino)-2,2-difluoropropanoate 1.80 (1 g, 3.0 mmol) in 
EtOH (5 mL) and trifluoroacetic acid (0.28 mL, 3.6 mmol), Pd(OH)2 ( 20 wt.% on 
carbon) (100 mg) was added and the reaction mixture was stirred for 48 h under 
hydrogen atmosphere. The reaction mixture was filtered and evaporated the solvent to get 
the product 3-ethoxy-2,2-difluoro-3-oxopropan-1-aminium 2,2,2-trifluoroacetate 1.93: 
yield 0.66 g (82%) 
1H NMR (400 MHz; DMSO-d6) 8 1.27 (t, J = 7.2 Hz, 3 H), 3.70 (t, J =16Hz, 2 H), 4.31 
(q, J = 7.2 Hz, 2 H) ppm. 
19F NMR (376 MHz; DMSO-dJCFCb) 8-74.03,-108.51 (t, J =17Hz) ppm. 
E thy I 3-(benzyloxycarbonylamino )-2,2-difluoropropanoate (1.92) 




3-Ethoxy-2,2-difluoro-3-oxopropan-1-aminium 2,2,2-trifluoroacetate 1.93 (1.22 g, 4.5 
mmol) was taken up in dichloromethane (10 mL) and added triethylamine (1.4 mL, 10 
mmol). The reaction mixture was cooled to 0 °C, benzyl chloroformate (0.7 mL, 4.95 
mmol) was added and allowed to stir for 4h at room temperature. Water was added to the 
reaction mixture and extracted with dichloromethane (3 x 20 mL). The organic layer was 
washed with IN HCl, dried over MgS04, and evaporated. The obtained residue was 
purified by column chromatography to gtve the product Ethyl 3-
(benzyloxycarbonylamino )-2,2-difluoropropanoate 1.92: 1.02 g (78%) 
1H NMR (400 MHz; CDCh) o 1.28 (t, J = 7.2 Hz, 3 H), 3.80 (m, 2 H), 4.26 (q, J = 7.2 
Hz, 2 H), 5.08 (s, 2 H), 7.32 (m, 5 H) ppm. 
13C NMR (100 MHz; CDCh) o 13.61, 43.59 (t, 2Jc-F = 28.1 Hz), 63.15, 67.13, 113.02 (t, 
1Jc-F = 251.2 Hz), 127.97, 128.11, 128.37, 135.87, 156.13, 162.81 (t, 2Jc-F = 31.1 Hz) 
ppm. 
19F NMR (376 MHz; CDCh/CFCh) o -112.22 (t, J = 13.7 Hz) ppm. 
E thy I 3-(tert-butoxycarbonylamino )-2,2-difluoropropanoate (1.94) 




3-Ethoxy-2,2-difluoro-3-oxopropan-1-aminium 2,2,2-trifluoroacetate 1.93 (0.42 g, 1.57 
mmol) was taken up in dichloromethane (5 mL) and pyridine (0.5 mL). The reaction 
mixture was cooled to 0 °C, di-tert-butyl-dicarbonate (0.343 g, 1.57 mmol) in 
dichloromethane (1 mL) was added and the mixture was allowed to stir for overnight at 
room temperature. Water was added to the reaction mixture and extracted with 
dichloromethane (3 x 20 mL). The organic layers were pooled, dried over MgS04, and 
evaporated. The obtained residue was purified by column chromatography to give the 
product ethyl 3-(tert-butoxycarbonylamino)-2,2-difluoropropanoate 1.94: yield 0.31 g 
(78%) 
1H NMR (400 MHz; CDCh) () 1.11 (t, J = 6.8 Hz, 3 H), 1.19 (s, 9 H), 3.53 (m, 2 H), 4.08 
(q, J = 7.2 Hz, 2 H) ppm. 
3-(benzyloxycarbonylamino )-2,2-difluoropropanoic acid (1.95) 
F. F H HO~NI(O'-./Ph 
0 0 
1.95 
To the solution of Ethyl 3-(benzyloxycarbonylamino )-2,2-difluoropropanoate 1.92 (0.5 g, 
1.74 mmol) in acetonitrile (13 mL), IN LiOH aqueous solution (13 mL) was added and 
52 
the reaction mixture was stirred for 3h. The solvent was evaporated and diluted with 
water ( 5 mL) and washed with ether (1 0 mL ). The aqueous phase was acidified with 1 N 
HCl (until pH 1) and extracted with ethyl acetate (3 x 20 mL). The solvent was 
evaporated, and the residue was purified by column chromatography to give the product 
3-(benzyloxycarbonylamino)-2,2-difluoropropanoic acid 1.95: 0.33 g (74%) 
I H NMR (400 MHz; CDCh) 8 3.72 (m, 2 H), 4.99 (s, 2 H), 7.23 (m, 5 H), 11.27 (s, 1 H) 
ppm. 
13C NMR (100 MHz; CDCh) 8 43.56 (t, 2Jc-F = 27.3 Hz), 67.52, 113.08 (t, 1 k-F = 250.4 
Hz), 127.99, 128.26, 128.49, 135.64, 156.79, 165.44 (t, 2Jc-F = 31.1 Hz) ppm. 
19 F NMR (376 MHz; CDCh/CFCh) 8 -112.78 (t, J = 13.7 Hz) ppm. 
(S)-Methyl 2-(3-(benzyloxycarbonylamino )-2,2-difluoropropanamido )-3-( 1 H-
imidazol-4-yl)propanoate (1.96) 
1.96 
3-(Benzyloxycarbonylamino)-2,2-difluoropropanoic acid 1.95 (147 mg, 0.567 mmol), 
histidine methylester hydrochloride (137 mg, 0.567 mmol) and 1-hydroxy benzotriazole 
(85 mg, 0.624 mmol) were taken up in dimethyl formamide (5 mL), stirred under 
nitrogen atmosphere, and treated with 4-methylmorpholine (0.15 mL, 1.13 mmol). The 
solution was cooled to -20 °C and dimethylaminopropyl-3-ethyl carbodiimide (120 mg, 
0.624 mmol) was added. The resulting solution was allowed to come slowly to room 
temperature and stirred for 24 h. The solvent was evaporated, saturated NaHC03 was 
53 
added, and the mixture was extracted with hot ethyl acetate (5 x 20 mL). The solvent was 
dried over MgS04 and concentrated. The residue was purified by column 
chromatography to give the product (S)-methyl 2-(3-(benzyloxycarbonylamino )-2,2-
difluoropropanamido)-3-(IH-imidazol-4-yl)propanoate 1.96: yield 182 mg (78%) 
I H NMR (400 MHz; CD30D) 8 3.06 (dd, J = 8.8 Hz, 15 Hz, 1 H), 3.16 (dd, J = 5.6 Hz, 
14.8 Hz, 1 H), 3.67 (s, 3 H), 4.74 (dd, J = 5.2 Hz, 8.4 Hz, 1 H), 5.07 (s, 2 H), 7.31 (m, 5 
H), 6.87 (s, 1 H), 7.57 (s, 1 H) ppm. 
uC NMR (100 MHz; CD30D) 8 29.43, 44.34 (t, 21c-F = 27.3 Hz), 52.99, 54.02, 67.82, 
116.29 (t, 'lc-F = 252.7 Hz), 117.72, 128.82, 129.02, 129.43, 134.61, 136.49, 137.94, 
158.67, 165.04 (t, 2Jc_F = 28.1 Hz), 172.31 ppm. 
19 F NMR (376 MHz; CD30DICFCh) 8 -112.86 (m) ppm. 
3-(tert-bu toxycarbonylamino )-2,2-difluoropropanoic acid (1.97) 
F. F H HO~NI(O'(-
o 0 
1.97 
Ethyl 3-(tert-butoxycarbonylamino )-2,2-difluoropropanoate 1.94 (280 mg, 1.11 mmol) 
was taken in 2:2:1 THF I MeOH I H20 (30 mL) and LiOH (28 mg, 1.162 mmol) was 
added. The reaction was allowed to stir at room temperature for 12 h. The volatiles were 
removed by rotary evaporation and the resulting aqueous solution was washed with 
dichloromethane (10 mL). The aqueous layer was then acidified with 10% citric acid 
solution and extracted with ethyl acetate (3 x 20 mL). The organic layers were combined, 
54 
dried over MgS04, and evaporated to get the product 3-(tert-butoxycarbonylamino )-2,2-
difluoropropanoic acid 1.97: yield 180 mg (72%) 
I 
H NMR (400 MHz; CDCh) ~ 1.45 (s, 9 H), 3.66 (t, J =14Hz, 2 H) ppm. 
I3c NMR (100 MHz; CDCh) ~ 30.76, 32.86, 45.95 (t, 2Jc-F = 26.5 Hz), 118.35 (t, 1Jc_F = 
250.5 Hz), 160.74, 172.26 (m) ppm. 
(S)-Methyl 2-(3-(tert-butoxycarbonylamino)-2,2-difluoropropanamido)-3-(1 H-
imidazol-4-yl)propanoate (1.98) 
3-(tert-Butoxycarbonylamino)-2,2-difluoropropanoic acid 1.97 (300 mg, 1.33 mmol), 
histidine methylester hydrochloride (323 mg, 1.33 mmol) and !-hydroxy benzotriazole 
(199 mg, 1.47 mmol) were taken up in dimethyl formamide (5 mL), stirred under 
nitrogen atmosphere, and treated with 4-methylmorpholine (0.3 mL, 2.67 mmol). The 
solution was cooled to -20 °C and added dimethylaminopropyl-3-ethyl carbodiimide (281 
mg, 1.47 mmol). The resulting solution was allowed to come slowly to room temperature 
and stirred for 24 h. The solvent was evaporated; saturated NaHC03 was added, and the 
solution was extracted with hot ethyl acetate (5 x 20 mL). The solvent was dried over 
MgS04 and concentrated. The residue was purified by column chromatography to give 
the product (S)-methyl 2-(3-(tert-butoxycarbonylamino )-2,2-difluoropropanamido )-3-
(IH-imidazol-4-y1)propanoate 1.98: yield 0.32 g (65%) 
55 
I 
H NMR (400 MHz; CD30D) 8 1.42 (s, 9 H), 3.13 (m, 2 H), 3.63 (t, J = 14.8), 3.70 (s, 3 
H), 4.72 (m, 1 H), 6.89 (s, 1 H), 7.61 (s, 1 H) ppm. 
I3c NMR (100 MHz; CD30D) 8 28.62, 29.51, 43.89 (t, 2Jc-F = 27.4Hz), 52.99, 54.00, 
116.27 (t, 1lc-F = 252.7 Hz), 117.86, 134.46, 136.50, 157.97, 165.15 (t, 2Jc-F = 28.1 Hz), 
172.28 ppm. 
19 F NMR (376 MHz; CD30D/CFCh) 8-113.13 (m) ppm. 
(S )-Methyl 2-(3-amin o-2,2-difluoropropanamido )-3-(1 H -imidazol-4-yl)propanoate 
(1.90) 
Procedure 1: Solution of eerie ammonium nitrate (1.37 g, 2.5 mmol) in water (8 mL) 
was added dropwise to the solution of PMP protected dipeptide 1.89 (191 mg, 0.5 
mmo )in 5 mL of acetonitrile. The reaction mixture was stirred for 2 h and the solvent was 
evaporated in vacuum. The residue was taken up in water and 5% NaHC03 was added 
until pH 7 was reached, and then 20% aqueous solution of NazS03 was added and the 
mixture was extracted with hot ethyl acetate (5 x 20 mL). The combined organic layers 
were washed with brine, and dried over MgS04. After filtration, the solvent was 
evaporated and the crude product was purified by column chromatography to obtain the 
product gem-difluoro analogue of camosme, (S)-methyl 2-(3-amino-2,2-
difluoropropanamido)-3-(lH-imidazol-4-yl)propanoate 1.90: yield 20mg (14%) 
56 
Procedure 2: (S)-Methyl 2-(3-(benzyloxycarbonylamino )-2,2-difluoropropanamido )-3-
(1 H-imidazol-4-yl)propanoate 1.96 (170 mg, 0.415 mmol) was taken up in MeOH (5 mL) 
and Pd ( 30 wt.% on carbon) (50 mg) was added. The reaction mixture was stirred for 36 
h under hydrogen atmosphere, filtered, and evaporated to get the product (S)-Methyl 2-
(3-amino-2,2-difluoropropanamido)-3-(IH-imidazol-4-yl)propanoate 1.90: yield 96 mg 
(84%) 
I H NMR (400 MHz; CD30D) () 3.08 (t, JH-F = 14.8 Hz, 2 H), 3.09 (dd, J = 5.6 Hz, 14.6 
Hz, I H), 3.20 (dd, J = 5.2 Hz, 15 Hz, 1 H), 3.72 (s, 3 H), 4.75 (m, 1 H), 6.89 (s, 1 H), 
7.61 (s, 1 H) ppm. 
13C NMR (100 MHz; CD30D/CDCh) o 27.57, 43.66 (t, 2Jc-F = 26.6 Hz), 51.48, 52.05, 
115.33 (t, 1Jc-F = 251.2), 115.84, 132.43, 134.52, 163.66 (t, 2Jc-F = 28.9 Hz), 170.43 ppm. 
19F NMR (376 MHz; CD30D/CFCb) o -114.25 (t, J = 14.5 Hz) ppm. 
N -(2-(1 H -imidazol-4-yl)ethyl)-2,2-difluoro-3-( 4-methoxyphenylamino )propanamide 
(1.99) 




2,2-Difluoro-3-( 4-methoxyphenylamino )propanoic acid 1.88 (300 mg, 1.3 mmol), 
histamine hydrochloride (239 mg, 1.3 mmol) and !-hydroxy benzotriazole ( 193 mg, 1.43 
mmol) were taken up in dimethyl formamide (5 mL), stirred under nitrogen atmosphere, 
57 
and treated with 4-methylmorpholine (0.3 mL, 2.6 mmol). The solution was cooled to -20 
°C and to it was added dimethylaminopropyl-3-ethyl carbodimide (274 mg, 1.43 mmol). 
The resulting solution was allowed to come slowly to room temperature and stirred for 24 
h. The solvent was evaporated, treated with NaHC03, and extracted with hot ethyl acetate 
(5 x 20 mL). The solvent was dried over MgS04 and concentrated. The residue was 
purified by column chromatography to give the product N-(2-(lH-imidazol-4-yl)ethyl)-
2,2-difluoro-3-(4-methoxyphenylamino)propanamide 1.99: yield 280 mg (62%) 
1H NMR (400 MHz; CD30D) () 2.70 {t, J = 7.2 Hz, 2 H), 3.41 (t, J = 7.2 Hz, 2 H), 3.66 (t, 
JH-F = 13.6 Hz, 2 H), 3.67 (s, 1 H), 6.64 {d, J = 9.2 Hz, 2 H), 6.72 {d, J = 9.2 Hz, 2 H), 
6.76 {s, 1 H), 7.62 (s, 1 H) ppm. 
13C NMR (100 MHz; CD30D) () 25.54, 38.67, 46.96 {t, 2Jc-F = 28.1 Hz), 54.32, 113.37, 
113.88, 115.86, 115.95 (t, 1Jc-F = 252 Hz), 134.04, 134.29, 141.41, 152.05, 164.29 (t, 
2Jc-F = 28.1 Hz) ppm. 




H F. F H N~N~NnO'-../Ph 
!!___ -~ 0 0 
N 
H 1.101 
3-(Benzyloxycarbonylamino)-2,2-difluoropropanoic acid 1.95 (178 mg, 0.687 mmol), 
histamine hydrochloride (126 mg, 0.687 mmol) and !-hydroxy benzotriazole (102 mg, 
58 
0.756 mmol) were taken up in dimethyl formamide (5 mL), stirred under nitrogen 
atmosphere, and treated with 4-methylmorpholine (0.15 mL, 1.374 mmol). The solution 
was cooled to -20 °C and dimethylaminopropyl-3-ethyl carbodiimidc ( 145 mg, 0. 756 
mmol) was added. The resulting solution was allowed to come slowly to room 
temperature and stirred for 24 h. The solvent was evaporated, saturated NaHC03 was 
added, and the mixture was extracted with hot ethyl acetate (5 x 20 mL). The solvent was 
dried over MgS04 and concentrated. The residue was purified by column 
chromatography to give the product benzyl 3-(2-(lH-imidazol-4-yl)cthylamino)-2,2-
difluoro-3-oxopropylcarbamate 1.101: yield 174 mg (72%) 
1H NMR (400 MHz; CD30D) o 2.77 (t, J = 7.2 Hz, 2 H), 3.44 (t, J ~= 7.2 Hz, 2 H), 3.73 (t, 
JH-F = 14Hz, 2 H), 5.06 (s, 1 H), 6.83 (s, 1 H), 7.25-7.31 (m, 5 H), 7.57 (s, 1 H) ppm. 
13C NMR (100 MHz; CD30D) o 27.37, 40.47, 44.38 (t, 21c-F = 28.1 Hz), 67.79, 116.42 (t, 
1Jc-F =252Hz), 117.63, 128.82, 129.02, 129.44, 135.80, 136.12, 137.97, 158.71, 165.19 
(t, 21c-F = 28.1 Hz) ppm. 
19F NMR (376 MHz; CD30D/CFCh) o -112.56 (t, h--11 = 13.7 Hz) ppm. 
N-(2-(1H-imidazol-4-yl)ethyl)-3-amino-2,2-difluoropropanamide (1.1 01) 
H F F N~N~NH2 
/(__ -~ 0 
N 
H 1.101 
Procedure 1: A solution ofceric ammonium nitrate (934 mg, 1.7 mmo1) in water (5 mL) 
was added dropwise to a solution of PMP-protected dipeptide 1.99 (120 mg, 0.3 7 mmol) 
59 
in 3 mL of acetonitrile. The reaction mixture was stirred for 2 h and the solvent was 
evaporated in vacuum. The residue was taken up in water treated with 5% NaHC03 until 
pH 7 was reached, and then 20% aqueous Na2S03 was added and the mixture was 
extracted with hot ethyl acetate (5 x 20 mL). The combined organic layers were washed 
with brine, and dried over MgS04. After filtration, the solvent was evaporated and the 
crude product was purified by column chromatography to obtain the product gem-
ditluoro analogue of carcinine, N-(2-(IH-imidazol-4-yl)ethyl)-3-amino-2,2-
ditluoropropanamide 1.100: yield 18 mg (22%) 
Procedure 2: Benzyl 3-(2-(1 H-imidazol-4-yl)ethylamino )-2,2-di fluoro-3-
oxopropylcarbamate 1.101 (98 mg, 0.278 mmol) was taken in MeOH (5 mL) and added 
Pd (30 wt.% on carbon) (50 mg). The reaction mixture was stirred for 36 h under 
hydrogen atmosphere, filtered, and evaporated to get the product N-(2-(1 H-imidazol-4-
yl)ethyl)-3-amino-2,2-ditluoropropanamide 1.100: yield 52 mg (86%) 
1H NMR (400 MHz; CD30D) a 2.82 (t, J = 7.2 Hz, 2 H), 3.11 (t, J11-F = 14.8 Hz, 2 H), 
3.50 (t, J = 7.2 Hz, 2 H), 6.87 (s, 1 H), 7.62 (s, 1 H) ppm. 
13C NMR (100 MHz; CD30D) a 27.32, 40.38, 45.40 (t, 21c-F = 26.5 Hz), 117.69 (t, 1k-F = 
249.7 Hz), 117.95, 135.69, 136.21, 165.83 (t, 2Jc-F = 28.1 Hz) ppm. 
19F NMR (376 MHz; CD30D/CFCh) 8-113.82 (t, J = 14.5 Hz) ppm. 
1.4.3 NMR spectra of the products 
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Figure 1.34: 13C NMR spectra of compound 1.80 
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Figure 1.35: 19F NMR spectra of compound 1.80 
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Figure 1.36: 1H NMR spectra of compound 1.81 
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Figure 1.37: 19F NMR spectra of compound 1.81 
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Figure 1.38: 1H NMR spectra of compound 1.83 
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Figure 1.40: 19F NMR spectra of compound 1.83 
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Figure 1.43: 13C NMR spectra of compound 1.87 
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Figure 1.45: 1H NMR spectr~ of compound 1.88 
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Figure 1.47: 19F NMR spectra of compound 1.88 
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Figure 1.48: 1H NMR spectra of compound 1.89 
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Figure 1.49: 1H spectra of compound 1.89 
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Figure 1.50: 19F NMR spectra of compound 1.89 
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Figure 1.52: 1H NMR spectra of compound 1.92 
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Figure 1.53: 13C NMR spectra of compound 1.92 
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Figure 1.54: 19F NMR spectra of compound 1.92 
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Figure 1.55: 1H NMR spectra of compound 1.94 
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Figure 1.56: 1H NMR spectra of compound 1.95 
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Figure 1.57: 13C NMR spectra of compound 1.95 
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Figure 1.59: 1H NMR spectra of compound 1.96 
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Figure 1.61: 19F NMR spectra of compound 1.96 
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Figure 1.63: 13C NMR spectra of compound 1.98 
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Figure 1.65: 1H NMR spectra of compound 1.90 
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Figure 1.67: 19F NMR spectra of compound 1.90 
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Figure 1.68: 1H NMR spectra of compound 1.99 
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Figure 1.69: 13C NMR spectra of compound 1.99 








Figure 1. 70: 19F NMR spectra of compound 1.99 
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Figure 1.71: 1H NMR spectra of compound 1.101 
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Figure 1.74: 1H NMR spectra of compound 1.100 
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Figure 1.76: 19F NMR spectra of compound 1.100 
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2. A NOVEL AND CONVENIENT SYNTHETIC METHOD FOR THE 
PREPARATION OF gem-DIFLUORODIARYLMETHYLENE COMPOUNDS 
2.1 INTRODUCTION 
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There has been considerable interest in the applications of gem-difluoro 
derivatives of organic compounds in biological and medicinal chemistry. Introduction of 
fluorine atom in the organic compounds changes their physical and chemical properties 
as well as biological activities. 1'2 The CF2 moiety has very similar van der Waals radius 
and electronic properties as those of oxygen atom, prompting the application of gem-
difluoro compounds as isosteric and isopolar analogues of ethers, which can be 
potentially used as enzyme inhibitors.3 For example, alkoxy or aryloxy oxygen in alkyl-
or aryl- phosphonates have been replaced with difluoromethylene group to increase their 
bioactivity.4 Such phosphonates with difluoromethylene group are hydrolytically stable 
and biologically more active than the corresponding non-fluorinated phosphonates. 
The transformation of CH2 to CF2 in organic compounds has been used to develop 
stable and potent compounds with higher resistance toward metabolic degradation. 
Recently, gem-difluoro-nucleosides have been developed to explore their medicinal 
applications.5•6 For example, 2' -deoxy-2', 2' -difluorocytidine (Gemcitabine) is currently 
one of the most effective and widely used anticancer drugs.7•10 gem-Difluoro-avermectin 
derivatives have been used as potent anthelminitic and anticonvulsant agents. 11 (2R)-2-
[(lR)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamides have been used as potent, 
. . t 12,13 




Figure 2.1: Structures of Gemicitabin and M3 antagonist 
A variety of methods have been developed to prepare gem-difluoromethylene 
compounds and these methods fall broadly in two classes.4' 14-17 They are direct gem-
fluorination approach and the fluorinated building block approaches. Direct fluorination 
is a powerful technique and particularly used at the final stages in synthetic schemes on 
stable intermediates which can withstand the often forcing reaction conditions. The 
building block approach is an effective method to incorporate CF2 synthon in organic 
compounds using easily accessible fluorinated building blocks. Methods of introducing 
fluorine directly are classified as nucleophilic and electrophilic fluorination methods 
based on the source of fluorine from fluorinated reagents. Here in this introduction, a 
short review of existing methods for direct fluorination is presented. 
2.1.1 Aldehydes and ketones to gem-difluoromethylene compounds: The 
transformation of aldehydes and ketones to difluoromethylene group is one of the most 
common and successful strategies to prepare difluoromethylene compounds. The 
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classical method to achieve this transformation uses sulfur tetrafluoride (SF4) with 
hydrogen fluoride as catalyst. 18-21 This method gives good yields for the desired products, 
but its use requires extremely cautious reaction conditions because of the toxicity, 
reactivity, and volatility ofSF4. In addition, special apparatus such as pressure equipment 
constructed of fluorine resistant material such as "Hastelloy-C" must be used and high 
temperatures are frequently necessary. Selenium tetrafluoride22 (SeF4) and 
moolybdenium tetrafluoride23•24 (MoF6) have been used for this transformation, but their 
application is limited because of their mildness in reactivity and involvement of hazards 
in their synthesis and use. These drawbacks have been circumvented to a greater extent 
by development of dialkylaminosulfur tetrafluoride. A series of these reagents have 
shown similar properties to SF4 in the transformation of carbonyl to gem-difluorination.25 
The pioneering work of Middleton is responsible for the development of 
diethylaminosulfur tetrafluoride (DAST), a commercially available liquid that requires 
less forcing reaction conditions than SF4 and standard laboratory apparatus. 26 DAST is 
tolerable to a variety of other functional groups and has been used across many classes of 
natural products and other biologically interesting systems.27 As an alternative to DAST, 
bis(2-methoxyethyl)aminosulfur trifluoride (Deoxofluor) has been developed. 
Deoxofluor is thermally more stable reagent and can transform aldehydes and ketones to 
d d 'ld . d' . 28 29 the corresponding gem-difluoromethylene compoun s un er mt reactton con thons. · 
DAST or Deoxofluor 
or SF4 or SeF4 
MeO~ 
Deoxofluor = N-SF3 
MeO______.f 
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Figure 2.2: Conversion of aldehydes and ketones to gem-difluoromethylene compounds 
Although the mechanism of DAST mediated gem-difluorination of carbonyl 
compounds has not been experimentally elucidated, the reaction may be initiated by the 
nucleophilic addition of HF (present in trace amounts in DAST) to the carbonyl group, 
followed by SN2-type reaction with DAST to give the a-fluoroalkoxydiethylaminosulfur 
difluoride and HF which further propagates the reaction. The a-
fluoroalkoxydiethylaminosulfur difluoride intermediate may undergo intramolecular 
transfer of fluoride ion from sulfur to carbon with the elimination of diethylaminosulfinyl 
fluoride (Et2NSOF). Alternatively a carbocation intermediate may be formed which is 
trapped by the fluoride ion (intermolecular). The formation of the carbocation 
intermediate, in some cases, is evidenced by the formation of the corresponding fluoro-
olefinic products. In polar solvents such as DMF, olefinic products are formed to a 
significant extent, while in nonpolar solvents such as CH2Ch, gem-difluoro-compounds 
d . 1 c. d 30-32 are pre ommant y 1orme . 
R'~R 
F 
(favored in DMF) 
HF 
(favored in CH2CI2) 
Figure 2.3: Mechanism of difluorination of carbonyl group with DAST 
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A similar reaction mechanism has been suggested for the SF4, SeF4, MoF6, and 
deoxofluor mediated gem-difluorinations. 
2.1.2 Hydrazones and Oximes to gem-difluoromethylene compounds: Hydrazone of 
aldehydes and ketones were transformed to the corresponding gem-difluoromethylene 
compounds using iodine monofluoride (IF) which is prepared from elemental 12, and F2.33 
Side reactions were observed in this procedure when a-proton elimination competes with 
the second fluorination. 
IF 
IF 
Figure 2.4: Conversion ofhydrazones to gem-difluoromethylene compounds using IF 
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Difluorination of hydrazones has also been effected by in situ generated 'BrF" 
usmg the combination of N-bromosuccinimide (NBS) and pyridinium polyhydrogen 
fluoride (PPHF).34 By using this procedure, the usage of hazardous elemental fluorine has 
been avoided for these reactions. 
NBS/PPHF 
R = e.g, H, Ph; Ph, Ph; 
Ph, 4-MeO-Ph; H, PhCH2 
Figure 2.5: Conversion ofhydrazones to gem-difluoromethylene compounds using 
NBS/PPHF 
The combination of NIS/PPHF gave unsatisfactory results for difluorination of 
hydrazones. Unsubstituted hydrazones have severe drawbacks such as instability and 
propensity for the formation of azines, which are unreactive to IF. 34 However, azines 
react with NBS/PPHF and BrF3 to form gem-difluoromethylene compounds. 
Oximes are unreactive with "BrF" but reacts with nitrosonium tetrafluoroborate 
(NOBF 4) to give good to excellent yields of the gem-difluoromethylene compounds. 35 A 
variety of oxime methyl ethers, 2,4-dinitrophenylhydrazones and azines react with BrF3 
to give their correspondinggem-difluoro derivatives in good yields.36 
cS 
Figure 2.6: Conversion of oximes to gem-difluoromethylene compounds 
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2.1.3 Dithioacetals and dithioketals to gem-difluoromethylene compounds: 
Dithioacetals and dithioketals derived from aldehydes and ketones were converted to the 
corresponding gem-difluoro-compounds by using 1 ,3-dibromo-5,5-dimethylhydantoin 
(DBH) or NBS with the presence of nucleophilic fluorine source PPHF in good yields. 37 
But here in these procedures, electrophilic ring bromination has occurred in case of 
electron rich aromatic systems and gave side products. 
n NBS or DBH FXF sxs 






Figure 2.7: Conversion of dithiolanes to gem-difluoromethylene compounds using 
NBS/PPHF and DBWPPHF 
S02Ch and S02ClF have been used as an alternative to the NBS as a source of 
electrophilic species in this transformation to facilitate the work up of the reaction, as the 
only byproduets of the reaction are the volatile S02 and HCl. 311 Nitrosonium 
tetrafluoroborate in the combination with PPHF has also been used for this 
transformation?9 The desulfurative fluorination of dithiolanes was also done by using 1-
diethylamino-1,1,2,2,3,3-hexafluoropropane in the presence of DBH as a source of 
electrophilic "Br+".40 1-Diethylamino-1,1,2,2,3,3-hexafluoropropane releases HF on 
reaction with water and thus acts as nucleophilic fluoride ion source in this reaction. BrF3 
is also an effective reagent to bring about the transformation of dithiolanes to gem-
d'fl 41-43 1 uoro compounds. 
Et2NCF2CHFCF3 
DBH/H20 
R =e.g., Ph, PhCH2, cycloalkyl 37-90% 
Figure 2.8: Conversion of dithiolanes to gem-difluoromethylene compounds using 
EtzNCFzCHFCF3 and DBH/H20 
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Motherwell and coworkers have developed a method for the desulfurative gem-
difluorination of dithiolanes by using p-iodotoulenedifluoride.44 .45 This reagent brings 
about the gem-difluorination by supplying electrophilic F1 ion for the electrophilic 
activation of dithiolanes, as well as nucleophilic fluoride ion for the fluorination of 




Figure 2.9: Conversion of diphenyl dithiolane to gem-difluoromcthylene compound 
using p-Iodotoulenedi fluoride 
This reaction is convenient for substrates involving stabilized carbocation as 
intermediates. The variously substituted versions of p-iodotoulenedifluoride were also 
prepared and used for difluorination of dithioketals. Dithiolanes were also transfom1ed to 
the gem-difluoro compounds by anodic desulfurization of dithiolanes in Et3N.3HF. The 
chemical oxidant can be replaced by an anode.46 The ketone 1,3-dithiolanes and acyclic 
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dithioketals were converted to corresponding gem-difluoro compounds by anodic 
fluorodesulfurisation using triethylamine tris(hydrogen fluoride)47 as fluoride source. In 
contrast aryl dithioacetals gave gem-difluoroethters and aliphatic dithioacetals gave 
monofluoroethers under the same conditions. Kuruboshi has reported the conversion of P-
hydroxy orthothioesters, derived from aldehydes, to ( 1, 1-difluoro-1-methylthio )ketones 
using oxidative desulfurisation conditions {TBATF/DBH)48• The oxidation conditions 








Figure 2.10: Conversion of P-hydroxy orthothioesters to 1, 1-difluoro-1-
methylthio )ketones 
2.1.4 Thiocarbonyls to gem-difluoromethylene compounds: The esters are relatively 
less electrophilic in nature compared to aldehydes and ketones and are unreactive in the 
presence of DAST. However, thioesters are more electrophilic than esters and are 
reactive toward DAST. Alkyl and aryl thioesters were easily prepared from esters using 
Lawesson's reagent and reacted with DAST to obtain the gem-difluoroethers in good 
yields.49 And also fluorodesulfurisation ofthioesters using BrF3 and TBATFINBS or NIS 
were reported to prepare gem-difluoroethers from thioesters.50'51 Methyl xanthates, 
ROCSSMe, underwent oxidative desulfurisation under similar conditions to afford 
difluoro( methylthio )methyl ethers, ROCF 2SMe. 52 
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DAST or BrF3 
or TBATF/NBS 
or TBATF/NIS 
Figure 2.11: Conversion of thiocarbonyls to gem-difluoromethylene compounds 
2.1.5 Azirines to gem-difluoromethylene compounds: 1-azirines were gem-
difluorinated using hydrogen fluoride as fluoride ion source. This is an useful method to 
prepare p,p-di tluoroamines from 1-azirines. This method has been applied to synthesis of 
3,3-di fluorophenylalanine. 53• 54 
PPHF 
Figure 2.12: Conversion azirines to 3,3-difluorophenylalanine 
2.1.6 Olefinic and acetylenic compounds to gem-difluoromethylene compounds 
2.1.6.1 Alkenyl trifluoroborates: Alkenyl trifluoroborates were reacted with two mole 
equivalents of selectfluor in water or acetonitrile solvents to obtain the corresponding 
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difluoromethyl substituted alcohols and amides, respectively.55 The intermediate, 
monofluoroalkene was isolated in these reactions. Alkenyl trifluoroborates were readily 
prepared from the corresponding alkenyl boronic acids by reacting with KHF2• 
KHF2 







Figure 2.13: Conversion of alkenyl trifluoroborates to gem-difluoromethyl substituted 
alcohols 
2.1.6.2 Alkenes: Alkenes were converted to the corresponding gem-difluoro compounds 
by reacting with xenon difluorides in the presence of Iz. This reaction follows the 
mechanism involving electrophilic addition of IF to alkenes, fluorine exchange with 
xenon difluoride forming idosodifluoride, 1,2-alkyl shift accompanying the elimination 
of IF2, and fluoride ion attack on the carbocation center to give gem-difluoro compounds 
as shown in the Figure 2.14 . 56 
0°C, 0.5 h 
0°C, 0.5 h 
~ F F XeF2 + 12 ::y XeF2 ~ [IF] 
I I~ 
F p- ~ ~ 
Figure 2.14: Conversion of alkenes to gem-difluoromethylene compounds and the 
mechanism for the difluorination of alkenes 
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2.1.6.3 Allylamines: Allylamines and diallylamines were reacted with HF-SbF5/NBS to 
obtain y-gem-difluoroamines. 57 This reaction follows the mechanism involving the initial 
formation ofthe cyclic bromonium ion which undergoes the 1,2-hydrideshift and fluoride 
ion capture to give y-bromofluoro compound. Later, protolytic elimination of HBr 









Figure 2.15: Conversion of allyl amines toy- gem-difluoroamine 
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2.1.6.4 Alkynes: Hydrofluorination of alkynes were reported to occur with Markownikov 
addition using poly 4-vinyl pyridinium poly(hydrogen fluoride) (PVPHF)58 and with the 
combination of KHF2 and SiF4• 59 Alkyl substituted alkynes were also converted to the-
CF2CX2 containing compounds by reacting with IF and BrF. Phenyl alkynes were prone 
to side reactions particularly with IF as the product undergoes further fluorination at the 
CI2 center. Fluoroalkenes were likely the intermediates in these reactions and it has been 
reported separately that 2-fluoro-1-alkenes undergo bromofluorination regioselectively 
under mild conditions. 60 The regioselectivity in these reactions was attributed to the 
ability of fluorine to stabilize a-carbocation by electron donating resonance. 
PVPHF 
NBS 
Figure 2.16: Conversion of alkyne to gem-difluoromethylene compound and 
bromo fluorination of alkene 
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Aryl substituted alkynes such as t-butyl phenyl acetylene, diphenyl acetylene 
were reported to react with Accufluor, (N-fluoro-N-Hydroxy-1 ,4-
diazobicyclo(2.2.2)octane bis(tetrafluoroborate)) in aqueous acetonitrile to give their 
corresponding a, a-difluoro-ketones. 61 
Ph-..::=--R 





Figure 2.17: Conversion of aryl substituted alkynes to a,a-difluoro-ketones 
2.1.7 Electrophilic difluorination: Banks and Lawrence have reported the difluorination 
of ~-ketoamides with Selectfluor under neutral conditions.62 The reaction times in these 
reactions were significantly reduced by carrying out the two fluorinations sequentially 
and with a sodium enolate of the monofluoro intermediate for the second step. The 
relative ease of fluorination depends on the proportion of the enol tautomer and the usage 
of enolate in the reaction. 
Selectfluor 
40 °C, 647h 
2. Selectfluor 
27h,rt 
Figure 2.18: Electrophilic difluorination of~-ketoamides with Selectfluor 
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Lactams were converted to a.,a.-difluorolactams by sequential reactions with 
lithium diisopropylamide (LDA) and Selectfluor.63 These difluorolactams were 
subsequently transformed to (L)-4,4-difluoroglutamic acid or its derivatives as shown in 
Figure 2.19. 
1. LDA, THF -78 °C 




1. LDA, THF -78 °C 
2. Selectfluor, THF, 
-78°C 
Figure 2.19: Conversion of a.,a.-difluorolactams to (L)-4,4-difluoroglutamic acid 
Methyl- or ethyl- aryl (a.,a.-difluoromethylenephosphonates) were prepared from 
their corresponding phosphonates using an excess of sodium hexamethyldisilazide 
(NaHMDS), and N-fluorobenzenesulfonimide (NFBS).64 This reaction tolerates a variety 
of functional groups in the aromatic ring, such as ester, ether, bromine, phenyl and nitro 
groups. 1 ,3-diaryl derived phosphonates were also converted to their corresponding 
benzylic gem-difluoro derivatives using the same conditions.64 However, this reaction 
was not successful for 1,4- diaryl derived phosphonates. 
1. NaHMDS (2.2 eq.), THF, -78 °C 
2. NFBS (2.5 eq.), THF, -78 °C 
X = e.g., H, ester, ether, Br, Ph, N02 
1. NaHMDS, THF, -78 °C 
2. NFBS, THF, -78 °C 








Figure 2.20: Conversion of aryl ( a,a-difluoromethylenephosphonates) to gem-
difluoromethylene compounds 
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Benzylic sulfonate esters were converted to their corresponding benzylic gem-
difluoro-sulfonate esters by difluorination at a-center using t-butyllithium followed by 
reaction with NFBS.65 
1. t-BuLi (2.2 eq.), THF, -78 °C 
2. NFBS (2.5 eq.), THF, -78 °C 
X= e.g., H, 4-N02, 4-Me 




Fig 2.21: Conversion of benzylic sulfonate esters to gem-dilfuoro-sulfonate esters 
2.2 RESULTS AND DISCUSSIONS 
Chambers and coworkers have prepared gem-difluoromethylene compounds by 
reacting dithiolane derivatives of diaryketones with elemental fluorine-iodine 
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mixtures.66'67 This same reaction in aqueous medium, however, resulted in the hydrolysis 
of the substrates to the corresponding carbonyl compounds. We have reasoned that the 
reaction of Selectfluor with PPHF may involve the transiently formed F2 which can bring 
about the desulfurative fluorination in case of dithiolanes. Alternatively the Selectfluor 
can serve as p+ releasing agent, able to react with thio compounds to give fluorothionium 






Figure 2.22: Possible activation ofthiolanes with the combination ofSelectfluor and HF 
2,2-diphenyl-1,3-dithiolane was prepared from 1,3-dithiolane and benzophenone 
using BF3.Etz0 as catalyst,68 and reacted with solutions of PPHF and Selectfluor. The 
reaction was rapid even at 0 °C in methylene chloride (CHzCh), and in about 5 min 
complete conversion of 2,2-diphenyl-1,3-dithiolane 2.1 to the corresponding gem-
difluoro compound 2.2 was observed in very good yield. GC/MS of the reaction mixture 
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Yiled = 86% 
Figure 2.23: Conversion of 1 ,2-diphenyl-1 ,3-dithiolane to gem-dilfuorodiphenylmethane 
With this promising result, several diaryl ketones were transformed into the 
dithiolanes using BF3.Et20 as catalyst, and the resulting dithiolanes were allowed to react 
with solutions of PPHF and Selectfluor. The reactions were rapid even at 0 °C, and in 
about 10 min complete conversion of the substrates to the gem-difluoro comounds was 
observed. Benzophenone dithiolanes, variously substituted with halogens or methyl 
groups, gave only the corresponding gem-difluoro compounds, as the single products, as 
shown by the GC/MS of the reaction mixture prior to the workup. 2-Adamantanone 
dithiolane 2.9 also gave quantitative conversion of the corresponding gem-difluoro 
compound 2.16 under these conditions. 
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Entry Dithiolane Product Yield(%) 
n 





oxo oxo 2 ~ ~ 80 
2.4 F F 2.11 
n 
oxo &0 3 76 ~ ~ 
2.5 Cl 2.12 Cl 
n 
OXQ JYO 4 62 
Cl Cl Cl 2.6 Cl 2.13 
n 
OXQ JYO 5 81 
F F F 2.7 F 2.14 
n 
oxo OXo 6 64 ~ OMe 
2•8 OMe 2.15 
S) F 
7 gts gtF 82 
2.16 
2.9 
Figure 2.24: Conversion diaryldithiolanes to gem-difluorodiarylmethanes 
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However, acetophenone-dithiolane 2.17 gave the corresponding gem-
difluoromethylene compound and the acetophenone in a ratio 6:4 under these reaction 
conditions. The dithiolanes derived from p-bromobenzaldehyde 2.20 and 
cyclododecanone 2.22 gave quantitative conversion to the corresponding carbonyl 
compounds. The lower yield observed for compound 2.17 and quantitative conversion of 
compounds 2.20 and 2.22 to the corresponding carbonyl compounds may be explained in 
terms of the relatively unstable nature of the incipient carbocation intermediates involved 














. · fd"tht"olanes from acetophenone, bromo-benzaldehyde and Ftgure 2.25: ReactiOn o 1 
cyclododecanone with Selectfluor/PPHF 
We have found that the reactions of dithiolanes with Selectfluor in aqueous 
. . . PPHF ave the corresponding carbonyl compounds as the only 
acetomtnle .or m aqueous g 
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reaction products, in accordance with the observations of Wong and coworkers. 69 And 
also there was no noticeable reaction observed for dithiolanes with either HF or 
Selectfluor alone in anhydrous CH2Ch under the reaction conditions used in this 
procedure. 
This reaction may involve the fonnation of the intennediate fluoro-sulfonium ion 
by the attack of the "F+" from the Selectfluor or the transiently fonned fluorine molecule. 
The fluoro-sulfonium ion then undergoes nucleophilic capture by the fluoride ion from 
the medium, and the process repeats to fonn the gem-difluoro compounds. If the 
intermediate carbocation fonned in the final desulfuration is not sufficiently long-lived, 







· 2 26 p d mechanism for the fonnation of gem-difluoromethylene F1gure . : ropose 
compounds from the carbonyl-dithiolanes and Selectfluor/PPHF 
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2.3 CONCLUSIONS 
The reaction between diaryldithiolanes with the combination of Selecttluor and 
PPHF gave the corresponding gem-difluoro compounds in good to excellent yields. This 
reaction is convenient, effective, and requires simple work up and mild reaction 
conditions. The hydrolysis of the dithiolanes derived from aromatic aldehyde and 
aliphatic ketone indicates that the reaction is only applicable to substrates which can 
generate stabilized carbocation as reaction intermediates. 
2.4 EXPERIMENTAL RESULTS 
2.4.1 General: All reagents were purchased from commercial sources and used as 
received. Colum chromatography was carried out using Merck 60, 230-400 mesh. Thin 
layer chromatography was carried out using silica gel coated polyester backed sheets. 
GC/MS spectra were recorded on Hewlett-Packard 5989A spectrometer, equipped with a 
Hewlett-Packard 5890 gas chromatograph. The 1H and 19F NMR spectra for CDCil 
solutions were obtained on a !NOVA-Varian 400 MHz spectrometer at 400, and 386 
MHz, respectively. The 1H NMR chemical shifts are referred to the internal TMS (8 = 
0.0). The 19F chemical shifts are referred to the internal CFCh (8 19F == 0.0). 
2.4.2 General procedure for the preparation of gem-difluoromethylene compounds: 
Selectfluor (0. 71 g, 2 mmol) was dissolved in PPHF (wt % HF : Py = 61 : 39) in a 50 m L 
polyethylene bottle and cooled to 0 °C. The dithiolane (I mmol) in dichloromethane (1 0 
mL) was added dropwise and allowed to stir for I 0 min at room temperature. The 
reaction mixture was then extracted with dichloromethane (3 X 30 mL), the combined 
organic layers were dried (MgS04), and the solvent was evaporated under reduced 
II I 
pressure. The residue was purified by column chromatography (silica gel, 2.0% dicthyl 
ether in hexane) to obtain gem-difluoromethylene product. 
2.4.3 Synthesis and properties of products 
Difluorodiphenylmethane (2.2) 
2.2 
Selectfluor (0.71 g, 2 mmol) was dissolved in PPHF (wt% HF: Py = 61 : 39) in a 50 mL 
polyethylene bottle and cooled to 0 °C. The benzophenone dithiolanc, 2.1, (0.26g, 1 
mmol) in dichloromethane (10 mL) was added dropwise and allowed to stir for 10 min at 
room temperature. The reaction. mixture was then extracted with dichloromcthanc (3 X 
30 mL), the combined organic layers were dried (MgS04), and the solvent was 
evaporated under reduced pressure. The residue was purified by column chromatography 
(silica gel, 2.0% diethyl ether in hexane) to give Difluorodiphenylmcthanc 2.2: yield 
0.17g (86%) 
MS: 204 (M+., 68), 183 (20), 127 (100), 107 (10), 77 (10) 
1H NMR (CDCb): o 7.85 (dd, 4 H, J =7Hz, J =1.1 Hz), 7.64 (tt, 2 H, J = 7.4 Hz, 1.46 
Hz), 7.54 (d, 4 H, J = 7.87 Hz) ppm. 
19F NMR (CDCb): o -89.3 (s) ppm. 





Prepared similarly to 2,2-phenyl-1,3-dithiolane 2.2. Yield 85%. 
MS: 282 (M+., 41), 203 (60), 183 (84), 127 (93), 107 (30), 77 (100) 
19 F NMR (CDCb): 8 -89.5 (s) ppm. 




Prepared similarly to 2,2-phenyl-1 ,3-dithiolane 2.2. Yield 80% 
MS: 222 (M\ 100), 203 (19), 145 (87}, 127 (77), 95 (18) 
19F NMR (CDCb): 8 -88.1 (s), -111.5 (s) ppm. 
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Prepared similarly to 2,2-phenyl-1,3-dithiolane 2.2. Yield 76% 
MS: 238(M+., 100), 219 (10), 203 (79), 161 (33), 127 (27) 
19 F NMR (CDCb): o -89.2 (s) ppm. 
bis( 4-Chlorophenyl)difluoromethane (2.13) 
Cl Cl 
2.13 
Prepared similarly to 2,2-phenyl-1 ,3-dithiolane 2.2. Yield 62% 
MS: 272 (M+., 50), 237 (67), 201 (18), 161 (100), 111 (27), 75 (41) 
19F NMR (CDCh): o -89.1 (s) ppm. 
ll3 
bis( 4-Fluorophenyl)difluoromethane (2.14) 
~ F~ llAF 
2.14 
Prepared similarly to 2,2-phenyl-1 ,3-dithiolane 2.2. Yield 81% 
MS: 240 (M+., 100), 239 (29), 221 (17), 201 (7), 145 (78) 
19 F NMR (CDCh): o -86.7 (s), -111.5 (s) ppm. 




Prepared similarly to 2,2-phenyl-1,3-dithiolane 2.2. Yield 64% 
MS: 234 (M+., 100), 203 (13), 157 (74), 127 (10), 77 (7) 
19F NMR (CDCh): o -87.2 (s) ppm. 
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2,2-Difluorotricyclo[3.3.1.1 ]decane (2.16) 
2.16 
Prepared similarly to 2,2-phenyl-1,3-dithiolane 2.2. Yield 82% 
MS: 172(M+., 14), 152(15), 109(25),93(41), 79(100),51 (71) 
19 F NMR (CDCh): o -100.2 (s) ppm. 
(1, 1-Difluoroethyl)benzene (2.18) 
ifF. F ~ 
.0 
2.18 
Prepared similarly to 2,2-phenyl-1,3-dithiolane 2.2. Yield 48% 
MS: 142 (M+., 34), 127 (57), 84 (100), 58 (74), 51 (44) 
19F NMR (CDCh): o -87.9 (q, J =18Hz) ppm. 
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2.4.4 NMR spectra of products: 
-
1 








Figure 2.29: .19F NMR spectra of compound 2.12 
-··· 
·IH 
I I • 













I u. .......... -
..,.... 
51 a -51 -110 -151 ., .. ~ 
Figure 2.31: 19F NMR spectra of compound 2.14 
Figure 2.32: 19F NMR spectra of compound 2.15 
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3. CARBENE CATALYZED TRIFLUOROMETHYLATIONS OF AROMATIC 
N-TOSYL-ALDIMINES 
3.1 INTRODUCTION 
3.1.1 Nucleophilic trifluoromethylation of imines: Trifluoromethyl-containing 
compounds have found a large number of applications ranging from biologically active 
drugs and agro-chemicals, to dyes and polymers. 1-3 In particular, the basicity of the amide 
bond is significantly reduced when the trifluoromethylated amines are incorporated into 
the peptides, due to the strongly electron withdrawing nature of the trifluoromethyl 
group. Thus, nonspecific proteolysis4 is attenuated when the latter amines are 
incorporated into the peptides. Further, these trifluoromethylated amines modify the 
solubility and desolvation properties5 of the derived peptides. A variety of methods have 
been reported in the literature for the preparation of trifluoromethylated amines6-10 and 
recently, the direct preparation of trifluoromethylated amines by nucleophilic 
trifluoromethylation has received much attention. A short survey of the existing methods 
for the preparation trifluoromethylated amines by nucleophilic trifluoromethylation using 
TMSCF3 or CF3VTDAE is presented below. 
Laurent and co-workers11 for the first time reported the trifluoromethylation of 
azirines using TMSCF3, and tetrabutylammonium fluoride (TBAF) as fluoride ion source. 
The reaction is catalytic in fluoride ion initiators (Figure 3.1 ). The formation of 
thermodynamically unfavorable silicon nitrogen bond occurred probably due to the 
release ofhigh strain from the structure ofazirine upon addition oftrifluoromethyl group. 
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TBAF, THF 
Figure 3.1: Nucleophilic trifluoromethylation of azirines 
Nelson and co-workers12 have reported the nucleophilic trifluoromethylation of 
nitrones with TMSCF3. Since nitrones are strongly electrophilic, they readily accept the 
trifluoromethide ion from TMSCF3 (Figure 3.2). The reactions proceeded smoothly at 
-78 °C, but the limited solubility of nitrones necessitated the use of higher temperature. 
The reactions were initiated by the addition of potassium tert-butoxide (t-BuOK). Other 
initiators such as KF and TBAF were ineffective as they yielded predominantly the 
addition-elimination products. 





THF, -78 °C 
Figure 3.2: Nucleophilic trifluoromethylation of nitrones 
Blazejewski and co-workers13 have reported the nucleophilic trifluoromethylation 
of normal imines with TMSCF3. N-Trimethylsilylimidazole (TMS-Imidazole) was used 
in this reaction as an additional silylating reagent (Figure 3.3). The success in addition of 
trifluormethide ion on imine was based on preventing the decomposition of the 
intermediate which has a labile N-Si bond by trapping it with suitable electrophile, using 
TMS-Imidazole. Lower yields for the desired trifluoromethylated amines were observed 
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due to the formation of byproducts, bistrifluoromethylated amme derivatives. The 
formation of bistrifluoromethylated amine derivative is thought to be due to the further 
attack of the trifluoromethide ion on the trifluoromethylated amine product. 
i) CF3 TMS I TMS-Imidazole 
ii) CsF I THF 
iii) Si02 12M HCI 
R1 =Ph, 2-Naphthyl, 2-Furyl, 3-MeOC6H4 
R2 = H, CF3, Me 
R3 = Ph, PhCH2, 3-CF3CsH4 
2-55% yield 
Figure 3.3: Nucleophilic trifluromethylation ofimines using TMSCF3 and TMS-
Imidazole 
Petrov14 have showed that N-aryl imines of hexafluoroacetone reacted with 
TMSCF3 in the presence of cesium fluoride (CsF). The reactions were rapid in THF or 




48 - 84% yield 
Figure 3.4: Nucleophilic trifluoromethylation of N-aryl imines ofhexafluoroacetone 
1n 2001, Prakash and co-workers15 have reported their first success in nucleophilc 
trifluoromethylation of N-Tosyl aldimines by using non-metallic fluoride source 
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tetrabutylammonium(triphenylsilyl) difluorosilicate16 (TBAT). N-Tosyl aldimines were 
used in these reactions to increase the electrophilicity of the imines and thus facilitating 
the attack of trifluoromethide ion on imines. When TBAF was used in these reactions, the 
products were obtained in lower yields with concomitant formation of trifluoromethane 
because of the strong hygroscopic nature of TBAF. The trifluromethylations of aromatic 
imines with electron withdrawing as well as electron donating group proceeded smoothly 
and gave the desired products in good yields. However, aliphatic sulfonamides and N-
Tosyl ketimines gave lower yields of the products. Subsequently, this methodology has 
been extended to N-(tert-butylsufinyl)-imines, 17 a,~-unsaturated N-(tert-butylsufinyl)-
imines18 and a-amino N-(tert-butylsufinyl)- imines19 to obtain the corresponding 
trifluoromethylated compounds in moderate to high yields. (Figure 3.6) 
1. TMSCF3, TBAT 
THF, 0- 5°C 
2. Work up 
Figure 3.5: Nucleophilic trifluoromethylation of N-tosylated amines using TBA T 
TBAT 
9F3 9 
R1~N ... S'tBu 
H 
R1 = p-CIC6H4, p-BrC6H4, 2-pyridyl, 2-furyl, Ph, 2-Naphthyl, tBu, PhCH2CH2 
TMAF 
Figure 3.6: Nucleophilic trifluoromethylations of N-(tert-butylsufinyl)- imines, a,p-
unsaturated N-(tert-butylsufinyl)- imines and a-amino N-(tert-butylsufinyl)- imines 
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Dolbier and co-workers20'21 have reported the nucleophilic trifluoromethylation of 
N-tosyl aldimines and N-tolyl sulfinimines using the nucleophilic trifluoromethylation 
reagent derived from CF3I and tetrakis(dimethylamino)-ethylene (TDAE). This 
methodology was limited to nonenolizable aldimines. (Figure 3. 7) 
DMF, -30 to 0 °C 
DMF, -30 to 0 °C 
Figure 3.7: Nucleophilic trifluoromethylation using CF3UTDAE 
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Mukaiyama and co-workers22-24 have reported catalytic trifluoromethylation of 
various aldimines with (trifluoromethyl)trimethylsilane in the presence of Lewis bases. 
Several lithium carboxylates such as lithium benzoate, acetate and pivalate were found to 
be effective bases in these reactions (Figure 3.8). However, weakly nucleophilic lithium 
trifluoroacetate did not promote this reaction. And also trifluoromethylation reactions did 
not proceed effectively in the presence of CsF and Lithium benzoate (BnOLi). 
Nucleophilic trifluoromethylation of N-sulfonylimines, N-sulfinylimines and N-
phosphonylimines proceeded smoothly in the presence of 10 mol% of lithium acetate. On 
the other hand, no trifluoromethylated products were observed when weak electrophiles 
such as N-phenylaldimine or N-benzylaldimine were used. Aromatic aldimincs with 
electron-withdrawing or electro-donating groups reacted smoothly to afford the 
trifluoromethylated products in good yields. Whereas aliphatic aldimines having a-
protons adjacent to the imino group reacted smoothly to afford the trifluoromethylated 
products in high yields, those with a-protons did not undergo the trifluoromethylation. 
AcOLi 
DMF, -30 °C 
AcOLi 
DMF, -30 °C 
AcOLi 
DMF, -40 °C 
Figure 3.8: Nucleophilic trifluoromethylation using Lewis base, AcOLi 
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Norio Shibata and co-workers25 have claimed that the P(t-Bu)3-DMF system 
effectively promoted the nucleophilic trifluoromethylation reaction of N-tosylated imines 
with TMSCF3. This reaction was limited to N-tosylbenzylaldimine and aromatic N-




Figure 3.9: Nucleophilic trifluoromethylation using P(t-Bu)3-DMF system 
3.1.2 N-Hetereocyclic carbene as a catalyst: N-Heterocyclic carbenes (NHCs) have 
received considerable interest in recent years. Excellent a-donating properties of NHCs 
make them ligands of choice for transition metals and have been successfully employed 
as ligands in a wide range of transition metal-catalyzed reactions26-30, as well as 
substrates in multi-component reactions31 -34• Further, they have been used as nucleophilic 
catalysts in various organic transformations such as transesterifications36-39, nucleophilic 
substitutions40-42, benzoin, and Stetter reactions.43-46 
Suzuki and co-workers47 have reported that N-heterocyclic carbenes produced in 
situ from salts of imidazolium, benzimidazole, pyrido[1,2-c]imidazolium, imidazolium, 
thiazolium, and triazolium catalyze the addition of trimethylsilylcyanide to aldehydes to 
yield cyanohydrin trimethylsilyl ethers. (Figure 3.10) 
azolium salts = 
0 






t-BuOK, TMS-CN/THF, rt 



























Figure 3.10: NHC catalyzed cyanosilylation of a-methoxybenzaldehyde 
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As suggested by the authors, the use of C2-symmetric imidazolidenyl carbene 
derived from (R,R)-1 ,3-bis[(l-naphthyl)ethyl]imidazolium presumably led to 
enantioselective cyanosilylation (Figure 3.11). They have also proposed a possible 
reaction pathway for the NHC catalysis. Carbene attacks the electrophilic center of the 
aldehyde and forms intermediate 3.2 which has been widely accepted in NHCs' catalysis. 
Intermediate 3.2 reacts with TMS-CN to produce intermediate 3.3 and cyanide anion. 
The cyanide anion nucleophilically attacks a carbon atom of 3.3. The imidazolium moiety 
of 3.3 acts as a leaving group, and nucleophilic substitution occurs to produce 
cyanohydrin silylether 3.4. In the case of the chiral NHC adds to aldehyde face 
selectively to produce diastereoisomeric intermediate 3.2 with an excess of a favored 
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isomer (Figure 3.12). The possible alternative catalytic mechanism was also discussed. 
In particular, the NHC activates TMS-CN by coordination (Figure 3.13). 
~OlH~OMe 
lXJ 
1. imidazolium salt, 




Figure 3.11: Asymmetric cyanosilylation catalyzed by chiral NHC 
· 3 12 p 'ble reaction pathway for NHC catalyzed cyanosilylation Ftgure • : osst 
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Figure 3~13: Alternative NHC catalytic mechanism for cyanosilylation 
Aoyama, Kondo, and co-workers48-50 have described the cyanation reaction of 
aldehydes, aldimines (Strecker reaction), ketones, and ketimines with TMSCN in the 
presence of 1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride and potassium tert-
butoxide, as a nucleophilic organocatalyst. These cyanation reactions afforded the 
corresponding products in good yields under mild reaction conditions. 
lmidazolium salt (10 mol%) 
KOt-Bu (9 mol%) 
TMSCN (1.2 equiv) 
lmidazolium salt (5 mol%) 
KOt-Bu (4 mol%) 
TMSCN (1.2 equiv) 
THF, 0 °C 
lmidazolium salt (5 mol%) 
KOt-Bu (4 mol%) 
TMSCN (1.2 equiv) 
DMF, r.t. 
lmidazolium salt (5 mol%) 
KOt-Bu (4 mol%) 
TMSCN (1.5 equiv) 




Figure 3.14: Cyanation of aldehydes, aldimines (strecker reaction), ketones, and 
ketimines in the presence ofNHC 
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N-Heterocylic carbenes have also reported to catalyze the ring opening of 
aziridines with silylated nucleophiles to afford the corresponding I ,2-difunctional 
products in excellent yields under mild reaction conditions. 51 
5mol% 
Me3SiX, 40 °C 
X= N3, Cl, I 
Figure 3.15: Reaction of aziridines with silylated nucleophiles catalyzed by NHC 
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3.2 RESULTS AND DISCUSSIONS 
Recently, Song and co-workers52 have reported that both enolizable and 
nonenolizable aldehydes and a-ketoesters underwent facile tritluoromethylation at room 
temperature in the presence of only 0.5-1 mol% of the N-heterocyclic carbene 3.5 to 
afford the corresponding trifluoromethyl-containing alcohols in good yields. Under NHC 
catalysis, selective trifluoromethylation of aldehydes over ketones was achieved. This 
method offered much greater catalytic efficiency as well as broader substrate scope 
compared to other Lewis base catalyzed trifluoromethylation methods. 
C)rN~NA ~ 3.5 \Y 
(0.5 mol%} 
Figure 3.16: NHC catalyzed trifluoromethylation of carbonyl compounds 
We envisioned that N-heterocyclic carbenes which have the reactivities similar to 
Lewis bases such as phophines and amines can activate TMSCF3 and can catalyze the 
trifluoromethylation of aldimines. According to that, first we have prepared the 
precursors, imidazolium chlorides for the N-heterocyclic carbenes using the procedure 
reported by Arduengo.53 Glyoxal diimines 3.6 and 3.7 were prepared by condensation of 
glyoxal with two equivalents of 2,4,6-trimethylphenylamine and 2,6-diisopropylamine 
t . 1 L t glyoxal diimines were cyclised with chloromethylethyl ether to obtain respec tve y. a er, 





3.6 and 3.8: R = y 










THF, 20- 40°C 





Figure 3.17: Preparation imidazolium chlorides 
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N-tosyl benzylaldimine 3.10 was prepared according to reported procedurc54 and 
reacted with TMSCF3 in the presence of N-heterocyclic carbene in THF solvent. N-
heterocyclic carbene was generated in situ through the reaction from 1 ,3-bis(2,4,6-
trimethylphenyl)imidazolium chloride 3.8 (1 0 mol%) and potassium tert-butoxide (9 
mol%). The reaction was allowed to stir for 12 hand quenched with water and extracted 
with ethyl acetate. The crude product has shown the peaks corresponding to the desired 
trifluoromethylated product in NMR and the product was isolated in trace amounts by the 
column chromatography. After this encouraging result, the reaction was conducted in a 
more polar solvent DMF. To our delight, the reaction was completed in 5h and afforded 
the product in 62% yield. Later, the reaction conditions were optimized and this led to 
72% yield for the trifluoromethylated N-(Tosyl)benzylamine with 15 mol% of 1,3-
bis(2,4,6-trimethylphenyl)imidazolium chloride and 13 mol% KOt-Bu. With the 
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optimized reaction conditions, the reaction was also conducted in the presence NHC 
generated from the reaction of 1,3-bis(2,6-diisopropylphenyl)imidazolium chloride 3.9 
and potassium tert-butoxide. The reaction was not complete even after 1 Oh and afforded 
the product in low yield (46%). 
e 
Cl 
-41®-)J-N N ~ !J \ I 
3.8 /Ts 




KOt-Bu (9 mol%) 
THF, RT, 12h 3.11 
3.10 Trace amounts 
e 
Cl 
-4H-9-,l$ -N, ~r ~ !J 
3.8 /Ts 
N.,....Ts (15 mol%) HN 
PhACF3 
Ph)lH 
+ TMSCF3 KOt-Bu (13 mol%) 
DMF, RT,4h 3.11 








N.,....Ts (15 mol%) HN 
PhACF3 
Ph)lH 
+ TMSCF3 KOt-Bu (13 mol%) 
DMF, RT, 10h 3.11 
3.10 yield= 46% 
. h 1 f of N-tosyl benzylaldimine in the presence ofNHCs Figure 3.18: Tnfluromet y a Ion 
138 
This methodology was extended to other aryl N-tosyl aldimines by reacting with 
TMSCF3 to obtain the corresponding trifluoromethylated sulfonamides. Aromatic N-tosyl 
aldimines with both electron-withdrawing and electro-donating groups on phenyl ring 
reacted smoothly to afford the trifluoromethylated products in moderate to good yields. 
Reactant Product Yield(%) 





dH ffcF3 75 
Cl Cl 
3.13 3.17 
N,...Ts /Ts HN dH ffcF3 78 
ON 02N 3.18 2 3.14 
N,...Ts /Ts HN dH dcF, 70 
H3C H3C 
3.15 3.19 
Figure J.19: Trifluoromethylation of aromatic N-tosyl aldimines in the presence of NHC 
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Reaction of aliphatic aldimine, cyclohexyl-N-tosyl aldimine55 with TMSCF3 in 
the presence of excess catalyst has provided the trifluoromethylated product in trace 
amounts, showing the peak corresponding to the product in 19F NMR. 
+ 
KOt-Bu (27 mol%) 





Figure 3.20: Trifluoromethylation of cyclohexyl-N-tosyl aldimine in the presence of 
N-heterocyclic carbene 
3.3 CONCLUSIONS 
N-Heterocyclic carbenes produced in situ from the imidazolium salts and 
potassium tert-butoxide were found to catalyze the nucleophilic trifluoromethylation of 
aromatic N-tosyl aldimines with TMSCF3. Aromatic N-tosyl aldimines with both 
electron-withdrawing and electron-donating groups underwent facile trifluoromethylation 
in the presence of the N-heterocyclic carbene (3.8) generated from 1 ,3-bis(2,4,6-
trimethylphenyl)imidazolium chloride and potassium tert-butoxide to afford the 
corresponding trifluoromethylated sulfonamides in moderate to good yields. The NHC 
catalyzed reaction is broadly applicable for the trifluoromethylation of substituted 
benzaldehyde imines. However, further optimizations are needed for the 
trifluoromethylation of aliphatic imines using this reagent. 
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3.4 EXPERIMENTAL RESULTS 
3.4.1 General: All reagents were purchased from commercial sources and used as 
received. Column chromatography was carried out using Merck 60, 230-400 mesh. Thin 
layer chromatography was carried out using silica gel coated polyester backed sheets. 
GC/MS spectra were recorded on Hewlett-Packard 5989A spectrometer, equipped with a 
Hewlett-Packard 5890 gas chromatograph. The 1H, 13C and 19F NMR spectra for CDC13 
and dmso-d6 solutions were obtained on a INOV A-Varian 400 MHz spectrometer at 400, 
100, and 386 MHz, respectively. The 1H NMR chemical shifts are referred to the residual 
solvents signals or the internal TMS (8 = 0.0). The 19F chemical shifts are referred to the 
internal CFCh (8 19F = 0.0). 
3.4.2 General procedure for the preparation of aromatic N-tosyl aldimines: 
Method A: The respective aromatic aldehyde (5 mmol), p-toulenesulfonamide (5 mmol) 
and tetraethyl orthosilicate (5.5 mmol) were combined in a round bottomed flask 
equipped with a still head and heated at 160 °C under nitrogen for 5 h, during which time 
ethanol formed was collected in the receiving flask. On cooling, ethyl ether (50 mL) was 
added and the suspended solids were filtered and washed with ethyl ether. The crude 
product was recrystallised in ethyl acetate/hexane to obtain the aromatic N-tosyl 
aldimine. 
Method B: The respective aromatic aldehyde ( 10 mmol) and p-toulenesulfonamide ( 1 0 
mmol) were added to a round bottomed flash containing 50 mL of toluene. The reaction 
mixture was heated at reflux for 25 h, with azeotropic removal of water using Dean-Stark 
apparatus. The reaction mixture was allowed to cool to room temperature, followed by 
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concentration on the rotary evaporator. The crude product was recrystallised in 
diisopropylether to obtain the desired aromatic N-tosyl aldimine. 
3.4.3 General procedure for the preparation of aliphatic N-tosyl aldimines: Aldehyde 
(10 mmol), p-toulenesulfonamide (10 mmol)and sodium p-toulenesulfinate were added to 
a round bottomed flask containing 15 mL of formic acid and 15 mL of water. The 
solution was stirred for 12 hat room temperature and the resulting white precipitate was 
filtered off, washed with water (2 x 10 mL), then with pentane (10 mL). The crude solid 
was dissolved in dichloromethane (100 mL) and was added sat. aq NaHC03 (70 mL). 
The solution was well stirred for 2 h at room temperature. The organic phase was 
decanted, the aqueous phase extracted with dichloromethane (70 mL) and the combined 
organic layers were dried (MgS04), filtered, and the solvent was removed under vacuum 
to obtain the aliphatic N-tosylaldimine. 
3.4.4 General procedure for trifluoromethylation of aromatic N-tosyl aldimines: 
Imidazolium chloride (15 mol%, 0.0724 mmol) was taken in 4 mL of DMF and was 
added potassium tert-butoxide (13 mol%, 0.063 mmol). After dissolution of imidazolium 
chloride (~20 min), aldimine (0.483 mmol) as solid and TMSCF3 (use either this or TMS-
CF3 consistently) (0.676 mmol) were added. The solution was stirred at room temperature 
for 4h, then quenched with water and extracted with ethyl acetate (3 x 15 mL). The 
organic layers were combined and successively washed with water and brine, dried over 
Na2so4 and concentrated. The crude product was purified by silica gel chromatography 
(10% EtOAc/Hexane) ~0 obtain the trifluoromethylated sulfonamide. 
142 
3.4.5 Synthesis and properties of products 
Glyoxal-bis-(2,4,6-trimethylphenyl)imine (3.6) 
3.6 
To a solution of 2,4,6-trimethylphenylamine (13.52 g, 0.1 mol) in 70 ml of n-propanol 
was added at room temperature a mixture of 40% aqueous solution of glyoxal (7.26 g, 
0.05 mol), 20 mL ofn-propanol and 10 ml ofwater. The mixture was stirred for 20h at r.t 
an then for 5h at 60 °C. Upon the addition of 40 mL of water, a yellow solid precipitated 
which was collected by filtration and dried in vacuum to obtain glyoxal-bis-(2,4,6-
trimethylphenyl)imine 3.6: yield 14.6 g (75%) 
1H NMR (400 MHz; CDCh) 8 2.15 (s, 12 H), 2.29 (s, 6 H), 6.90 (s, 4 H), 8.09 (s, 4 H), 
8.13 (s, 2H) ppm. 
Glyoxal-bis-(2,6-diisopropylphenyl)imine (3. 7) 
3.7 
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To a solution of 2,6-diisopropylphenylamine (9.85 g, 0.056 mol) in 50 mL of n-propanol 
was added at room temperature a mixture of 40% aqueous solution of glyoxal (3.63 g, 
0.028 mol), 5 mL of n-propanol and 15 ml of water. The mixture was stirred for 2h at 70 
°C. Upon the addition of 40 mL of water, a solid precipitated which was collected by 
filtration and dried in vacuum to obtain glyoxal-bis-(2,6-diisopropylphenyl)imine 3.7: 
yield 8.63 g (82%) 
1H NMR (400 MHz; CDCb) 5 1.21 (d, J = 6.8 Hz, 12 H), 2.94 (septet, J = 6.8 H, 4H), 
7.18 (m, 12H), 8.10 (s, 2H) ppm. 





To a solution of chloromethylethyl ether (1.45 g, 15.38 mmol) in 9 ml ofTHF was added 
I · f 1 1 bt·s (2 4 6-trimethylphenyl)imine 3.6 (4.5 g, 15.38 mmol) in 100 mL a so utwn o g yoxa - - , , 
of THF. The flask was sealed under nitrogen with a septum and the mixtutre was stirred 
A l.d began to appear after 1 hand the stirring was continued at r.t at room temperature. so I 
h c. d solid precipitate was collected by filtration to obtain I ,3-bis-for 5 days. T e 1orrne 
(2,4,6-trimethylphenyl)imidazolium chloride 3.8: yield 1.68 g (32%) 
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I 
H NMR (400 MHz; dmso-d6) o 2.12 (s, 12 H), 2.34 (s, 6 H), 7.19 (s, 4 H), 8.32 (s, 2H), 
9.84 (s, IH) ppm. 







To a solution of chloromethylethyl ether (1.8 g, 18.30 mmol) in 3 mL of THF was added 
glyoxal-bis-(2,6-diisopropylphenyl)imine 3. 7 ( 6.89 g, 18.30 mmol in 40 mL of TH F and 
2 drops of water. The flask was sealed under nitrogen with a septum and the mixtutrc was 
stirred at 40 °C. A solid began to appear after I h and the stirring was continued at the 
same temperature for 16h and then the mixture was allowed to cool to room temperature 
and precipitate was collected by filtration to obtain I ,3-bis-(2.6-
diisopropylphenyl)imidazolium chloride 3.9: yield 3.88 g (50%) 
1H NMR (400 MHz; dmso-d6) o 1.14 (d, 1 = 6.8 Hz, 12 H), 1.24 (d. 1 :== 6.8 Hz, I 2 H). 
2.33 (sept, J = 6.8 Hz, 4 H), 7.51 (d, J = 8.0 Hz, 4 H), 7.67 (t, 1 = 7.6 Hz, 2 H), 8.56 (s. 2 
H), 10.20 (s, I H) ppm. 
4-Methyl-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide (3.11) 
0 HN-~~CH3 d'CF3 
3.11 
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Imidazolium chloride 3.8 (25 mg, 0.0724 mmol) was taken in 4 mL of DMF and was 
added potassium tert-butoxide (7 mg, 0.063 mmol). After dissolution of the imidazolium 
chloride (~20 min), aldimine 3.10 (125 mg, 0.483 mmol) as solid and TMSCF, (0.1 mL, 
0.676 mmol) were added. The solution was stirred for at room temperature tor 4h, then 
quenched with water and extracted with ethyl acetate (3 x 15 mL). The organic layers 
were combined and successively washed with water and brine, dried over Na2S04 and 
concentrated. The crude product was purified by silica gel chromatography (I 0% EtOAc) 
to obtain 4-Methyl-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide 3.11: yield 114 
mg (72%) 
1H NMR (CDCh): 8 2.34 (s, 3H), 4.90 (q, J = 7.5 Hz, 1 H), 5.11 (b, I H), 7.12-7.33 (m, 7 
H), 7.59 (d, J = 8.4 Hz, 2 H) Ppm. 
19F NMR (CDCb): 8-74.36 (d, J = 7.6 Hz) ppm. 
4-Methyl-N-(2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)benzenesulfonamide (3.16) 
0 dHN-~D-CH3 CF3 
F 3.16 
Prepared similarly to 3.7. Yield 82% 
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1H NMR (CDCh): o 2.36 (s, 3 H), 4.84-4.92 (m, 1 H), 5.74 (d, J = 8.8 Hz, 1 H), 6.90-
6.95 (m, 2 H), 7.14-7.17 (m, 4 H), 7.58 (d, J = 8.4 Hz, 2 H) ppm. 
19F NMR (CDCh): o -74.6 (d, J = 7.5 Hz), -112.0 (s) ppm. 
N-(1-(4-Chlorophenyl)-2,2,2-trifluoroethyl)-4-methylbenzenesulfonamide (3.17) 




Prepared similarly to 3.7. Yield 75% 
IH NMR (CDCh): 0 2.32 (s, 3 H), 4.78-4.86 (m, 1 H), 5.61 (d, J = 9.2 Hz, 1 H), 7.04-
7.19 {m, 6H), 7.52 (d, J =8Hz, 2 H) ppm. 
19F NMR (CDCh): o -74.4 (d, J == 7.6 Hz) ppm. 
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4-Methyl-N-(2,2,2-trifluoro-1-( 4-nitrophenyl)ethyl)benzenesulfonamide (3.18) 
Prepared similarly to 3.7. Yield 78% 
1H NMR (CDCh): 8 2.35 (s, 3 H), 4.98-5.06 (m, 1 H), 6.19 (d, J = 9.2 Hz, 1 H), 7.16 (d, J 
= 8.0 Hz, 2 H), 7.40 (d, J = 8.4 Hz, 2 H), 7.59 (d, J = 8.4 Hz, 2 H), 8.08 (d, J = 8.8 Hz, 2 
H) ppm. 
19F NMR (CDCh): 8 -74.0 (d, J = 7.6 Hz) ppm. 
4-Methyl-N-(2,2,2-trifluoro-1-p-tolylethyl)benzenesulfonamide (3.19) 




Prepared similarly to 3.7. Yield 70% 
IH NMR (CDCh): 8 2.21 (s, 3 H), 2.28 (s, 3 H), 4.75-4.83 (m, 1 H), 5.73 (d, J = 9.2 Hz, 1 
H), 6.95-7.00 (m, 4 H), 7.07 (d, J = 8.4 Hz, 2 H), 7.53 (d, J = 8.4 Hz, 2 H) ppm. 
19p NMR (CDCh): 8-74.2 (d, J = 8.0 Hz) ppm. 
3.4.6 NMR spectra of products: 
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Figure 3.21: 1H NMR spectra of compound 3.6 
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Figure 3.23: 1H ,NMR spectra of compound 3.8 
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Figure 3.24: 1H NMR spectra of compound 3.9 
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Figure 3.25: 19F NMR spectra of compound 3.11 
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Figure 3.26: 1H NMR spectra of compound 3.16 
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Figure 3.27: 19F NMR spectra of compound 3.16 
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Figure 3.28: 1H NMR spectra of compound 3.17 
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Figure 3.29: 19F NMR spectra of compound 3.17 
e•ll lt'IUII 
.Mtf'L I 
...... ... .. 11 "'' toh•nt CICia 
.,,. ... 
ACOlllllfl-




"' ..... . ,.~ ... . 
~· u tpw 15 
.. ' ·' It I 












'" "' •• ... 
,._ 
DIIPlAV 







' Ill u . n 





DIC . a '<liT 
.. ,.... "' ·"' !iln Hl 
tilt'!" •• 
.. , ' 
.. ... 














Figure 3.30: tH NMR spectra of compound 3.18 
152 





&TAHD .... O PAIIIAMITflltl 
u p1 stpul 
IAMPLt: 
data Kllr U 1117 
tolvant COC13 
'' 1:COUnntON .,.., 
tfrq 111 . 1.U 
tn ,11 
at 1 . 111 
,., 111131 
• .., 111111 . 1 
t'b Ullt 
bl u 
t pwr 55 
pv S . t 
•• 0 




gatn not u tad 
flAOI 
ore . a. vT 
=~,. .. Jtt . 7:~ 
dpvr Jl 
















" not 11tH , 
" 







we Ill h••• •.•• 
.. , ..... 
rfl tll.Jt . a 
,.,, . 
th 11 
tns U .I . IU 
n11 no ph 
r-~~----.-~~~~-r~~~~-r-r~~-r~-r-r-~~~~----~--------~-T~~---1 ~ 
-7&.00 -7&.05 -7& . 10 -7& . 11 - 7& . 11 - 7& .11 
-73 . !15 
-73 . 85 -73.!10 
Figure 3.31: 19F NMR spectra of compound 3.18 
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